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Cancer-related fatalities rank as the second leading cause of death in all
ages and both genders in the United States. Moreover, breast cancer-related
mortality rank as the second leading cause of death in females in the United States
in 2019. The main concerns regarding breast cancer management include
chemotherapy resistance and metastasis. Thus, the advanced understanding of
cancer progression is required to develop improved therapeutic methods for breast
cancer patients.
Recent studies demonstrate that neutrophils, as the most abundant
leukocytes, play an essential role in breast progression. However, the mechanisms
regarding neutrophils recruitment to the tumor sites, and the precise role of
neutrophils in the tumor microenvironment, together with the specific mechanisms
of neutrophil stimulated cancer progression remains unclear.
Therefore, this dissertation mainly investigated the role of IL17-CXCR2 axis,
which positively promotes the recruitment of tumor-associated neutrophils to the
tumor sites, and how tumor-associated neutrophils facilitated cancer progression.
Our results indicated that there were higher levels of CXCR2, CXCR2 ligands, and
IL17R present on the resistant and metastatic tumors. In addition, resistant tumors
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recruited higher levels of neutrophils and Th17 cells. Moreover, our experimental
results revealed that IL17 facilitated cancer cell proliferation and secretion of
CXCR2 ligands, which resulted in increased neutrophil chemotaxis; additionally,
the neutrophil chemotaxis was dependent on CXCR2 signaling. We also observed
that the neutrophils facilitated cancer progression through multiple mechanisms,
including upregulation of IL1β and CCLs, and the formation of neutrophil
extracellular traps (NETs). When cultured in chemotherapy-resistant tumor cells’
supernatant, the neutrophils especially possessed elongated survival time and
secretion of MMP2 and MMP9.
Moreover, our studies indicated the differences between the chemotherapyresistant tumor microenvironment and the non-resistant tumor microenvironment,
which indicates why patients with established chemo-resistance result in lower
survival rates. Our experimental results showed the therapeutic biomarkers for
these patients and facilitated the improved clinical benefits for cancer patients in
the future. In addition, our studies demonstrated that neutrophils could be
considered as therapeutic targets and biomarkers for breast cancer patients,
shedding light on an improved therapeutic strategy for breast cancer treatment.
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CHAPTER I: INTRODUCTION

This chapter in part is derived from:
Wu L, Saxena S, Awaji M, Singh RK. Tumor-Associated Neutrophils in Cancer: Going
Pro. Cancers, 2019, 11, 564-583. DOI:10.3390/cancers11040564.
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SIGNIFICANCE OF THE STUDY
Breast cancer is one of the most common cancer types that impacts
females worldwide. Generally, the treatments for early-stage breast cancers are
effective, contrary to late-stage, when the malignancies spread to distant organs.
Currently, the primary treatments for breast cancer include chemotherapy,
radiation, and surgery. The working mechanisms of chemotherapy drugs usually
involve inhibiting DNA synthesis as well as cell replication, cell mitosis, or inhibiting
topoisomerases. However, cancer cells can quickly develop therapy resistance
through mechanisms including a decrease in drug intake, increase in drug efflux,
or epithelial to the mesenchymal transition (EMT), and changes in the tumor
microenvironment. Through these mechanisms, tumor cells relapse and
metastasize to distant organs even after treatment. Consequently, there is an
urgent need for an effective therapeutic plan for breast cancer patients.
Recent evidence suggests that interactions among pro-inflammatory
cytokines, chemokines, and cancer cell-recruited neutrophils result in enhanced
metastasis and chemotherapy resistance. These factors significantly affect the
therapeutic response and the overall outcome of patients. This study presents an
effort to discover the role of interleukin 17 (IL17), CXCR2 ligands, and cancerassociated neutrophils in chemotherapy resistance and metastasis in breast
cancer. Overall, our results contribute to understanding how the IL17-CXCR2 axis
facilitates the recruitment of neutrophils to the tumor sites, and how the neutrophils
influence cancer progression through complex mechanisms. This study also
reveals the differences between chemotherapy-resistant and non-resistant tumor
2

microenvironment and the cancer metastasis process. The results obtained from
this study facilitates a better understanding of the breast cancer microenvironment,
establishment of an advanced therapeutic plan, and prognostic indicator for breast
cancer patients in the future.
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OVERVIEW OF THE FEMALE BREAST: ANATOMY AND PHYSIOLOGY
Anatomy and Histology:
The breast tissue overlays the pectoral muscle, usually, extending from the
second to the sixth rib. The normal female breast is made up of three major parts:
the lobules that are responsible for milk production (12-20 sections together as
lobes), ducts that are responsible for transferring milk, and the adipose tissue
(fatty, connective tissue which links the lobules, ducts, and related circulation
vessels). The majority of breast cancer cases begin in the ducts (most common)
and lobules (5% to 15% of all breast cancer cases) (Varga and Mallon 2008).
The lymph node system that connects to breast tissue plays an essential role
for breast cancer progression; the tumor cells often metastasize from nearby lymph
vesicles, and establish secondary sites in the lymph node, then further metastasize
to distant organs through the circulation system. However, around one-third of
patients do not establish distant metastasis in 10 years after treatment (Weigelt,
Peterse, and van 't Veer 2005).
The breast tissue is composed of epithelial cells (luminal and myoepithelial
cells), stromal cells (interlobular and Intralobular stroma). The breast tissue is
mainly composed of two main structures (large ducts and terminal ductal lobular
unit).
The

primary

function

of

the

breast

includes

nourishment

and

immunoprotection for infants. The epithelial and stromal cells of breast tissue are
hormone-responsive, so the breast continuously changes during lifetime due to the
4

life cycle (menarche, pregnancy, lactation, and menopause) as the hormone levels
change.
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BREAST CANCER
Epidemiology
Breast cancer is the most common cancer that happens to females
worldwide (Tao, Shi, Lu et al. 2015). Compared to other cancer types, breast
cancer has the highest incidence and ranks as the second leading cause of death
in females in the United States in 2019 (Siegel, Miller and Jemal 2019). As a
heterogeneous disease, breast cancer patients have various outcomes, ranging
from excellent prognostics to aggressive tumors (Tao, Shi, et al. 2015). The death
rates regarding breast cancer have consistently declined by 1.8% per year, due to
the improved screening technique, females’ heightened awareness of changes in
the breast, and the improved therapeutic plans. Still, invasive breast cancer
incidence rates increased by 0.4% per year in females in the United States
(American Cancer Society, 2018).
Early detection methods for breast cancer include self-diagnosis and
mammography (X-ray).

The common symptoms for breast cancer include a

painless or swelling lump under the arm due to metastasis of the tumors to the
nearby lymph node, or other less common symptoms include pain in the breast,
swelling of the skin, or nipple abnormality (American Cancer Society 2018).
However, some patients are not diagnosed until a later stage due to the
unnoticeable symptoms (when the tumor size is small) and limitations of the
mammography technique. Once patients are diagnosed with breast cancer, they
will receive various treatment plans according to the stage and type of cancer. The
therapeutic plan may include chemotherapy administrations, surgical removal of
6

the tumor section, hormone therapy, immunotherapy, and radiation. Patients who
receive surgical treatments may also receive breast reconstruction surgery
(American Cancer Society, 2019).
The five-year survival rate for breast cancer patients with localized tumors
is 99%; however, because some patients are already at the metastatic stage when
diagnosed, the overall breast cancer patients’ five-year survival rate is between
83% to 90% (American Cancer Society 2019). Survival rates for breast cancer
patients are also associated with age: according to previous studies, the survival
rates for breast cancer declined markedly in females after the age of 49 (Adami,
Malker, Holmberg, et al. 1986).
Risk Factors
By far, there is no definitive cause for the occurrence of breast cancer
described in previous studies. However, multiple risk factors significantly increase
when breast cancer occurs, including age, race/ethnicity, and genetics (American
Cancer Society, 2018).
Age is positively associated with breast cancer incidence and death rates
(Kelsey 1979, American Cancer Society, 2018). At the same time, early age of
menarche, late age of menopause, and late age of first full-term pregnancy are
linked to a modest increase in the risk of developing breast cancer (Kelsey,
Gammon and John 1993). Other than age, race/ethnicity also plays a vital role in
breast cancer occurrence; from 2006 to 2015, Hispanic and non-Hispanic white
women had increased breast cancer incidence rates of 0.3% to 0.4%. Black (non-
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His-panic) and American Indian/Alaska Native females had increases of breast
cancer incidence rates of 0.7% to 0.8%; while Asian/Pacific Islander women had
a 1.8% per year incidence rates of breast cancer in the United States (Siegel,
Miller, et al. 2019). However, the non-Hispanic white and Hispanic women had the
highest incidence and death rates for breast cancer than the other two
race/ethnicity groups (American Indian/Alaska Native female groups and
Asian/Pacific Islander groups). The Asian/Pacific Islander females have the lowest
incidence and death rates (American Cancer Society, 2019).
Females who have a family history of breast cancer will possess higher
incidence rates. The risk ratios for breast cancer grow with increasing numbers of
affected first-degree relatives of the females (Collaborative Group on Hormonal
Factors in Breast 2001). Breast cancer clusters in families are associated with
gene mutations; the most well-studied are the BRCA genes (BRCA1 and BRCA2).
Based on the previous studies, the BRCA1 mutation carriers demonstrate a breast
cancer risk of 54% by the age of 60 (95% confidence interval 27%-71%) (Easton,
Ford and Bishop 1995). However, other than mutations of highly penetrant genes
including BRCA1, the lower penetrance gene mutations are more often seen in the
majority of breast cancer families with less than four cases and no ovarian cancer
(Ford, Easton and Peto 1995).

8

Histological classification of breast cancer subtypes
Breast adenocarcinoma constitutes over 95% of breast cancer cases
(Makki 2015). Breast carcinoma can be divided into two major groups: in situ
carcinoma and invasive carcinoma (Malhotra, Zhao, Band, et al. 2010). In-situ
carcinoma can be further classified as ductal carcinoma (more often) or lobular
carcinoma. The invasive carcinoma can be further classified as infiltrating ductal,
invasive lobular, ductal/lobular, mucinous (colloid), tubular, medullary, and
papillary carcinomas (Malhotra, Zhao et al. 2010). For invasive breast cancer,
invasive ductal carcinoma accounts for 55% of breast cancer incidence (Makki
2015). However, the histological classification of breast cancer only depends on
the histology of the breast tissue, which leads to the advanced classification of
breast cancers by molecular markers.
Molecular classification of breast cancer subtypes
Considering that breast cancer is a heterogeneous disease, traditional
histology classifications for breast cancer would not reflect detailed information,
such as the prognosis of the patients or the possibility of patients’ response to
therapeutic drugs (Pusztai, Mazouni, Anderson, et al. 2006). Thus, the molecular
markers are used for the classifications of breast cancer, especially in invasive
ductal carcinoma, the utility of molecular markers are well accepted (Malhotra,
Zhao, et al. 2010).
The molecular classification of breast cancer was firstly proposed in 2000
(Perou, Sorlie, Eisen, et al. 2000). The molecular markers used for classifications
of breast cancer are estrogen receptors (ERs), progesterone receptors (PRs), and
9

human epidermal growth factor receptor 2 (HER2) (Trop, LeBlanc, David, et al.
2014). According to the receptor expression, breast cancer can be divided into
several different subgroups: luminal breast cancer (luminal A and luminal B,
reflecting ER, ER regulatory genes, and other gene expressions in normal luminal
epithelial cells); HER-2 positive breast cancer (reflecting ErbB2/HER-2
amplification and overexpression); basal breast cancer (reflecting ER, PR, and
HER-2 negative and other gene expressions in normal breast basal and
myoepithelial cells), and a normal-like breast cancer (samples with low tumor cell
content and more normal tissue components) (Eliyatkin, Yalcin, Zengel et al.
2015). The molecular classification of the breast cancer type suggests the
selection of chemotherapy drugs for the patients (Andre and Pusztai 2006).
Functional classification of breast cancer subtypes
The functional classification of breast cancer subtypes is based on the
cancer stem cell theory. Cancer stem cell theory states that tumor cells originate
in either tissue stem cells or immediate progenitor cells, and because of this, the
tumor contains a cellular population that possesses the cancer stem cell
properties, which includes self-renewal (tumorigenesis driver) and aberrant
differentiation that contributes to cellular heterogeneity (Wicha, Liu and Dontu
2006). Additionally, cancer stems cells slowly divide and have an inherent
resistance to therapies (Song and Miele 2007).
The cancer stem cells are marked using the stem cell markers such as
CD44/CD24, ALDEFLUOR (ALDH1), CD49f/α6-integrin, and CD29/β1-integrin
(Malhotra, Zhao, et al. 2010). By far, the cancer stem cell theory is debatable.
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However, there is preclinical evidence regarding the existence and the role of
cancer stem cells in breast cancer progression; also indicating cancer stem cells
play pivotal roles in cancer risk assessment, early detection, prognostication, and
prevention (Wicha, Liu, et al. 2006). For instance, cancer cells that survived
chemotherapy administration demonstrated higher percentages of stem cell
marker CD44+CD24- expression (Li, Yi and Wu 2008). Moreover, in our previous
studies, we also observed that Cl66 cells (murine breast cancer cells) that were
resistant to doxorubicin or paclitaxel expressed higher levels of stem cell marker
(ALDH1) compared with non-resistance cells (Sharma, Varney, Saxena, et al.
2016). Targeting cancer stem cell markers may result in the elimination of cancer,
tumor formations, and higher sensitivity to therapeutic drugs. (Economopoulou,
Kaklamani and Siziopikou 2012).
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CURRENT STUDIES ON BREAST CANCER
Overview
Histologically,

the

most

common

breast

cancer

type

is

breast

adenocarcinoma; meanwhile, among the invasive breast cancer, the most
common breast cancer type is invasive ductal carcinoma (Makki 2015). As other
common cancer types, the survival rates for breast cancer patients are very high
when the cancer is localized. However, the survival rates become significantly
lower once the malignancies metastasize to remote organs (Siegel, Miller, et al.
2019).
The primary treatments for breast cancer include chemotherapy, radiation,
and surgery (Hsu, Jou and Tsai 2019). The working mechanisms of chemotherapy
drugs usually involve inhibiting DNA synthesis as well as cell replication, cell
mitosis, or inhibiting topoisomerases (Dutcher, Novik, O'Boyle, et al. 2000).
However, cancer cells can quickly develop therapy resistance through
mechanisms including a decrease in drug intake, increase in drug efflux, or EMT,
and changes in the tumor microenvironment (Zahreddine and Borden 2013, Jo,
Choi, Kim et al. 2018). Through these mechanisms, tumor cells relapse and
metastasize to distant organs even after treatment. Consequently, there is an
urgent need for an effective therapeutic plan for breast cancer patients.
Previous studies demonstrate that the tumor microenvironment plays a
crucial role in cancer metastasis (Peinado, Zhang, Matei, et al. 2017). The tumor
microenvironment significantly affects the therapeutic response and the overall
outcome of the patients. Recent evidence suggests that interactions among pro12

inflammatory cytokines, chemokines, and cancer cell-recruited neutrophils in the
tumor microenvironment resulting in enhanced metastasis and chemotherapy
resistance (Wu, Saxena, Awaji, et al. 2019). Nonetheless, the detailed mechanism
remains unclear. In the following sections, we will discuss the positive regulators
(CXCR2-IL17 axis) of neutrophils recruitment in the tumors, the role of neutrophils
in the tumor microenvironment, and the precise mechanism in neutrophils
facilitated breast cancer progression.
Breast cancer chemotherapy resistance and metastasis
The understanding of breast cancer has advanced dramatically in recent
years, which led to an improved therapeutic plan for breast cancer patients, thus
results in improved survival rates. Currently, chemotherapy drugs such as
doxorubicin and paclitaxel are routinely given to cancer patients as a form of an
injection or oral administration. Conventional chemotherapy is one of the main
therapeutic methods for treating cancer patients and decreases cancer relapse
and metastasis, which further results in longer survival times in most patients (Liu,
Lv and Yang 2015).
Chemotherapy resistance is commonly seen in every type of breast cancer
and severely affects the outcome of patients. After the administration of
chemotherapy drugs, the shrink and relapse of tumors are frequently seen. Once
the patients develop chemotherapy resistance and metastasize to remote organs,
the patients' survival rates also become low. Therefore, to improve therapeutic
plans for cancer patients, there is an urgent need for understanding the precise
mechanism of cancer chemotherapy resistance.
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Cancer metastasis happens when the tumor cells mobilize from the original
sites, then colonize distant organs through entering the circulation system (Steeg
2016). Inhibition of cancer metastasis remains the major challenge regarding
cancer studies, as most of the cancer therapy drugs target the present tumor
lesions, instead of preventing tumor metastasis (Steeg 2016). Like other cancer
types, once metastasized to distant organs such as the lung, breast cancer
patients’ survival rates become significantly lower (Siegel, Miller, et al. 2019).
Metastasis contributes to the primary cause of death for cancer patients, and it
seems that prevention of metastasis requires the cooperation of multiple reagents,
other than solely administrating one single drug to patients (Steeg 2016).
The breast cancer tumor microenvironment
The tumor microenvironment plays a crucial role in most cancer types,
including breast cancer (Lim, Woodward, Wang, et al. 2018). Recent studies
revealed that the tumor is not only made up of heterogeneous tumor cells but also
made up of other factors such as resident and infiltrating cells (for example,
immune cells including neutrophils), the secreted factors (for instance, chemokines
such as CXC chemokines, or cytokines such as TNF-α), and the extracellular
matrix proteins (Coffelt, Wellenstein and de Visser 2016). All those players
constitute the tumor microenvironment, and educate the tumor cells, orientating
them to the direction of metastasis, chemotherapy resistance, or dormancy.
Recently, there are immunotherapeutic drugs that are especially targeting the
immuno-checkpoint, which results in significantly improved patients outcomes,
such as drugs that target PD1, PD-L1, or chimeric antigen receptors (CAR)-T cell
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therapy. However, more immuno-therapeutic methods are necessary to cure
cancer patients (Zhang and Chen, 2018).
Recently, the tumor-associated neutrophils were found to play a vital role in
cancer progression, implying neutrophils or neutrophils secreted factors can be
considered as a biomarker or therapeutic target for breast cancer patients (Coffelt,
Wellenstein, et al. 2016). Neutrophils are the most abundant leukocyte in the
human immune system, and the role of neutrophils in the tumor microenvironment
is not yet understood. However, according to the scientific reports, infiltrated
polymorphonuclear (PMN) cells in the tumor are associated with the worst
outcomes for cancer patients (Gentles, Newman, Liu, et al. 2015). This result
indicates neutrophils’ significance in cancer progression. This study mainly
examined the role of neutrophils in breast cancer, and the precise mechanisms
regarding neutrophil promoted cancer progression. The clinical significance of
neutrophils will also be further discussed later in this chapter.
Clinical trials for breast cancer patients
To develop an improved therapeutic plan or breast cancer prevention, which
promotes better survival for breast patients, scientists are developing multiple
clinical trials. According to the National Cancer Institute (NIH), currently, there are
over 818 breast cancer clinical trials on-going, for instance, weight-loss
interventions in treating overweight and obese women with a higher risk for breast
cancer recurrence; doxorubicin hydrochloride and cyclophosphamide followed by
paclitaxel with or without carboplatin in treating patients with triple-negative breast
cancer; cisplatin with or without veliparib in treating patients with recurrent or
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metastatic triple-negative and /or BRCA mutation-associated breast cancer with or
without brain metastases.
The clinical trials of breast cancer include trying a new combination of
current therapeutic drugs or therapeutic methods, or invention of new drugs that
can especially target the cancer cells. In this study, we aim to reveal the role of
CXCR2-IL17 axis in neutrophil recruitments in breast cancer. We hope the results
we obtained will facilitate the invention of new therapeutic targets.
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IL17 SIGNALING IN BREAST CANCER
Overview
Cytokines are small secreted peptides released by cells and possess the
interactive communication and regulative effects between cells. The cells can
release the cytokines and act upon the same cell (autocrine), nearby cells
(paracrine), or on distant cells (endocrine). The cytokines include lymphokine
(cytokine produced by lymphocyte), monokine (cytokine produced by monocyte),
chemokine (cytokines with chemotactic activities), and interleukin (cytokine
produced by leukocyte and regulate other leukocyte activities) (Zhang and An,
2007). The production of cytokines can be induced by multiple stimuli, for instance,
other cytokines (Guo, Junttila and Paul 2012), lipopolysaccharide (LPS) (Rossol,
Heine, Meusch, et al. 2011), and viruses (Mogensen and Paludan 2001).
Interleukins, as key members in the cytokine family, play a dedicated
regulation role in allergy, asthma, autoimmune diseases, tumor development,
organ transplantation, and chronic infections. Recently, over 40 kinds of
interleukins were identified (Akdis, Burgler, Crameri, et al. 2011). Among those
interleukins, the interleukin 17 A (IL17) is the central driver of host response and
inflammation, thus closely associated with chronic inflammation and cancer.
IL17 A was first cloned from an activated T cell in 1993, with an initial name
of CTLA-8 (cytotoxic T-lymphocyte-associated antigen 8) (Rouvier, Luciani, Mattei,
et al. 1993). The IL17 A protein is 57% homologous to the putative protein encoded
by the ORF13 gene of herpesvirus Saimiri, a T lymphotropic virus, suggesting IL17
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A may belong to virus-captured genes and play an essential role in the immune
system.
The IL17 family consists of six members, IL17A-F. Since IL17A is the most
notable member of the family, it is also known as IL17. IL17 was found to
upregulate the expression levels of various cytokines and chemokines, including
granulocyte colony-stimulating factor (G-CSF) (Hirai, Iyoda, Shibata et al. 2012),
IL6, CCL2 (MCP-1) (Hata, Andoh, Shimada et al. 2002), and CXCR2 ligands (Li,
Jiang, Hu et al. 2017). Through the upregulation of these factors, IL17 plays critical
roles during inflammation and tumor progression.
The major contributors of IL17 are Th17 cells, which are found in various
tissues; however, other cell types can produce IL17, such as CD8+ T cells, γδ T
cells, NK cells, and neutrophils (Rouvier, Luciani, et al. 1993). The Th17 cells
originate from CD4+ T cells. Other than producing IL17, Th17 cells are categorized
as the production of IL17F, IL-6, tumor necrosis factor α (TNF-α), and IL-22
(Schmidt-Weber, Akdis and Akdis 2007). The differentiation of Th17 cells in mice
is modulated by transforming growth factor-beta (TGF-β) and IL-6 (Sandquist and
Kolls 2018). Additionally, other factors essentially regulate Th17 differentiation,
such as IL-23 (Bhaumik and Basu 2017). The differentiation of naive CD4+ T cells
to Th17 cells requires the regulation of other cytokines such as IL-23 and IL-6
(Sandquist and Kolls 2018). In some instances, the IL17 could also be produced
by neutrophils (Werner, Gessner, Lilly, et al. 2011).
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The function of IL17 requires the interaction between IL17 and the IL17
receptor (IL17R). The founding receptor of the IL17R family is IL17RA, which has
the largest cytoplasmic tail of the IL17R family. The large cytoplasmic tail of IL17R
can provide docking sites for multiple signaling intermediates (Gaffen 2009). The
IL17 is a dimeric protein and preferentially binds to the receptor complex made up
of one molecule of IL17-RA and one molecule of IL17-RC. After binding to IL17RA,
the IL17 molecule undergoes a conformational change on the IL17 dimmer, which
allows the selection of a different receptor polypeptide to bind to the dimmer, and
completion of the cytokine-receptor complex (Liu, Song, Chrunyk, et al. 2013).
IL17 signaling during inflammation
As a pro-inflammatory cytokine, IL17 plays key roles during inflammation.
IL17 overexpression results in tissue inflammation, together with matrix
destruction, autoimmunity, and vascular activation (Miossec and Kolls 2012). IL17
can upregulate pro-inflammatory chemokines or cytokines such as G-CSF or
CXCR2 ligands (Hirai, Iyoda, et al. 2012), which results in higher recruitment of
neutrophils, and leads to higher inflammation (Zenobia and Hajishengallis 2015).
The underlying mechanisms regarding IL17 induced upregulation of chemokines
and cytokines might be because of the signaling pathways activated by IL17,
leading to enhanced de novo gene transcription and also control of mRNA stability
(Amatya, Garg and Gaffen 2017).
The overproduction and expression of IL17 are found to be associated with
multiple inflammatory diseases, such as rheumatoid arthritis, psoriasis, Crohn's
disease, and multiple sclerosis (Miossec 2009). Blocking IL17 prevented late19

stage chronic destructive arthritis and the spontaneous development of arthritis
(Lubberts 2008). Other than inducing the expression of CXCR2 ligands, IL17 can
also upregulate and synergize with other pro-inflammatory mediators, such as IL1, TNFα and RANKL (NF-κB signaling ligands) (Lubberts 2008), which implies IL17
is a crucial mediator for inflammation. IL17 could be considered as a therapeutic
target for patients with inflammatory disorders. Potentially, there are two ways to
target IL17: directly utilizing the IL17 neutralizing antibody (already used for
treating psoriasis), or inhibition of Th17 differentiation.
IL17 expression and signaling in breast cancer
As inflammation is intimately linked with cancer initiation and progression,
it is not surprising that IL17, as the key regulator for inflammation, also plays a vital
role in cancer. The secretion of IL17 in breast cancer cases was reported, such as
IL17 levels that are positively correlated with breast cancer metastasis; IL17
expression levels decreased to at least 100-fold in non-metastatic tumors
compared to metastatic breast cancer tumors (Eiro, Fernandez-Garcia, Gonzalez,
et al. 2013). Recombinant IL17 upregulated ERK signaling in breast cancer cell
lines, promoting cell proliferation, and resistance to chemotherapy drugs, including
docetaxel. IL17 also promoted breast cancer cells migration and invasion
(Cochaud, Giustiniani, Thomas, et al. 2013); additionally, another mouse model
revealed that IL17 could promote TGF- β dependent tumor growth and inhibited
breast tumor cells apoptosis (Nam, Terabe, Mamura et al. 2008, Fabre,
Giustinniani, Garbar, et al. 2018).
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According to the previous reports, the IL17 can activate MAPK and NF-κB
signaling,

thus

facilitating

tumor cells

proliferation,

invasion,

migration,

angiogenesis, and resistance to therapeutic reagents.
Additionally, the pro-tumor role of IL17 occurs through the upregulation of
CXCR2 ligands (Li, Jiang, et al. 2017), thus positively regulating neutrophils’
recruitment and functions (Akbay, Koyama, Liu, et al. 2017). In breast cancer
mouse models, the production of IL17 resulted in the expression of G-CSF,
together with the polarization of neutrophils; the polarized neutrophils resulted in
immunosuppression in the tumor microenvironment (suppression of CD8+ T cell
function), and further metastasis (Coffelt, Kersten, Doornebal, et al. 2015).
Moreover, IL17 is positively linked with neutrophil numbers in the tumor
microenvironment. In breast cancer models, IL17 was found to increase the
secretion of CXCL1 and CXCL5 by mammary carcinoma cells, which further
facilitates cancer progression (Novitskiy, Pickup, Gorska, et al. 2011).
Consequently, higher levels of IL17 presenting in breast cancer patients correlate
with lower survival rates of the patient (Yang, Kang, Fung, et al. 2014).
All those results imply the importance of IL17 during cancer progression,
and IL17 could be considered as a therapeutic marker for breast cancer patients.
However, the detailed mechanisms regarding IL17 facilitated cancer progression
remain unknown. In this dissertation, we will be focusing on the precise mechanism
of IL17-CXCR2 axis facilitated tumor progression.
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CHEMOKINES IN BREAST CANCER
Overview
Chemokines are cytokines that have chemotactic activity (Mogensen and
Paludan 2001), which regulate the migration patterns and positions of all related
cells. Chemokines also play important roles in cell functions, survival, and
differentiation (Griffith, Sokol and Luster 2014, Sharma, Varney, et al. 2016).
Chemokines are critical regulators for the innate and adaptive immune system. By
far, there are around 50 types of chemokines, and 20 types of chemokine receptors
(G protein-coupled receptor) found (Griffith, Sokol, et al. 2014). Chemokines are
categorized into four families according to the conserved N-terminal cysteine
residues in mature ligands, which are CXC family, CC family, CX3C family, and C
family (Huang, Chen, Gong, et al. 2008). In this dissertation, we will mainly focus
on the CXC family receptor and chemokines.
Generally, the chemokines and their receptors are crucial regulators for
cancer progression. However, the detailed mechanisms are not fully understood.
Cancer cells themselves can produce chemokines, and stimulate angiogenesis,
metastasis, and therapy resistance (Wente, Keane, Burdick et al. 2006, Sharma,
Nawandar, Nannuru et al. 2013, Sharma, Varney et al. 2016); additionally, the
recruited immune cells are also able to contribute higher levels of chemokines,
which results in higher mobilization of other immune cells, leading to the further
progression of cancer. For instance, the CXCR2 ligands recruited tumorassociated neutrophils to the tumor sites (Wu, Saxena et al. 2019); meanwhile, the
recruited neutrophils were reported to contribute to higher levels of CCL2 and
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CCL3 to the tumor microenvironments (Tsuda, Fukui, Asai, et al. 2012).
Additionally, according to the previous report, the CCL2 positively regulated the
pro-tumor macrophage to the tumor sites and cooperated with CCL3 to promote
cancer metastasis (Kitamura, Qian, Soong, et al. 2015). All these results indicated
the interactive communications between the cancer cells to immune cells, immune
cells to immune cells in the tumor microenvironment through the secretion of
chemokines.
CXCR2 chemokines
As introduced before, CXC, CC, CX3C, and C chemokines consist of the
chemokine family (Huang, Chen, et al. 2008). The CXC chemokines can be further
divided into two subgroups: one group contains the glutamic acid-leucine-arginine
(ELR) motif, while one group does not. Seven CXC chemokines contain ELR motif,
which is CXCL1 to 3, and CXCL 5 to 8, and they all possess a high binding affinity
for CXCR2 (Veenstra and Ransohoff 2012), a G-protein coupled receptor that
spans the membrane seven times. The CXCR2 and CXCR2 chemokine/ligands
are potential therapeutic targets for multiple diseases including cancer, as they are
the crucial regulators for neutrophils mobilization from bone marrow, and the
neutrophils, as the critical part of the innate immune system, play key roles in
inflammatory reactions and cancer (Veenstra and Ransohoff 2012). Additionally,
CXCR2 ligands play a pro-angiogenesis role and pro-chemotherapy resistance
role in cancer (Sharma, Nawandar et al. 2013, Sharma, Varney, et al. 2016). The
role of CXCR2 and CXCR2 ligands in cancer progression will be further discussed
later in this chapter.
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CXCR2 signaling during inflammation
CXCR2 chemokines are known as pro-inflammatory chemokines and
positively mediated multiple processes during inflammation, mostly through their
positive regulatory role on neutrophil recruitment, as neutrophils are the first and
major responder for inflammation. Inhibition of CXCR2 signaling demonstrated
attenuated inflammation in most of the cases (Jee, Mourya, Shivakumar et al. 2017,
Feng, Zhou, Ma et al. 2018), because the recruitment of neutrophils (the hallmark
of inflammation) requires the positive regulation of CXCR2 and negative regulation
of CXCR4 (Martin, Burdon, Bridger, et al. 2003). Once recruited to the inflamed
sites, the neutrophils control the microbe population through mechanisms
including phagocytosis, secretion of proteases, and formation of neutrophil
extracellular traps (NETs) (Bhattacharya, Wei, Shin, et al. 2015). The regulatory
role of CXCR2 on neutrophil mobilization might be through the PDZ scaffold
protein NHERF1 coupling CXCR2 to its downstream effector phospholipase C
(PLC)-β2, which results in intracellular calcium mobilization, chemotaxis, and the
transepithelial migration of neutrophils (Wu, Wang, Farooq et al. 2012).
The expression of CXCR2 is found mostly on neutrophils (Stadtmann and
Zarbock 2012); however, could be on other cell types to regulate inflammation
such as cancer cells, macrophage, or endothelial cells (Sharma, Nawandar et al.
2013, Feng, Zhou et al. 2018, Haarmann, Schuhmann, Silwedel et al. 2019). For
instance, the expression of CXCR2 on human cerebral microvascular endothelial
cell line hCMEC/D3 strongly increased during inflammation and disturbed the
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blood-brain barrier under inflammatory conditions with increased CXCL5 and
CXCL8 expressions (Haarmann, Schuhmann et al. 2019).
Angiogenesis is closely linked with inflammation; meanwhile, CXCR2
signaling plays a key role in the angiogenesis process (Clavel, Valvason, Yamaoka,
et al. 2006).

CXCR2 is positively involved in angiogenesis, and inhibition of

CXCR2 resulted in activation of Akt and extracellular signal-regulated kinase
(ERK), which led to reduced pulmonary angiogenesis in common bile duct ligation
rats (Li, Chen, Chang, et al. 2017).
CXCR2 signaling in breast cancer
Based on previous studies, CXCR2 signaling is potent pro-tumor signaling,
through the recruitment of neutrophils into the tissue, which promotes tumor
initiation and tumor-favored inflammation. Additionally, inhibition of CXCR2
profoundly suppresses the tumor-favored inflammation and tumorigenesis
(Jamieson, Clarke, Steele, et al. 2012).
CXCR2 exerts pro-angiogenesis effects in multiple cancer cases, including
breast cancer (Matsuo, Raimondo, Woodward et al. 2009, Sharma, Nawandar, et
al. 2013). In ER-negative breast cancer, knocking down the CXCR2 ligand
expression significantly reduced the microvessel density in a murine breast cancer
model (Yao, Lin, Chua, et al. 2007). In cancer cases, the induction of CXCR2
ligands is by other pro-inflammatory factors, including TNFα and interleukin-1β (IL1β) (Liu, Li, Tian, et al. 2016). CXCR2 signaling further activates signalings such
as phosphoinositide-3-kinase (PI3K), mitogen-activated protein kinase (MAPK),
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phospholipase C (PLC), and non-receptor tyrosine kinases and Rho-GTPases to
facilitate tumor cells mobilization, proliferation, and chemoresistance (Liu, Li et al.
2016).
According to our previous studies, the tumors that survive initial chemo- and
radiation therapies expressed higher levels of CXCR2 ligands and targeting
CXCR2 enhanced the therapeutic response of chemotherapy drugs (Sharma,
Nawandar, et al. 2013). Breast cancer cells that established a resistance to
chemotherapy drugs expressed higher levels of CXCR2 ligands, stem cell, and
mesenchymal markers, also have higher metastatic abilities compared with nonresistant tumor cells. Meanwhile, neutralizing CXCR2 ligands resulted in
significant tumor growth inhibition (Sharma, Varney, et al. 2016).
Moreover, CXCR2 signaling promotes cancer progression through the
regulations on tumor-associated neutrophils. As the most abundant leukocyte,
neutrophils play essential roles in the tumor microenvironments. We will talk about
the interactions between CXCR2 and neutrophils in the next part of the introduction.

26

TUMOR-ASSOCIATED NEUTROPHILS IN BREAST CANCER
Overview
Neutrophils (originated from the myeloid precursor) composed the essential
parts of the white blood cells and are the major responder for innate immune
system response (Coffelt, Wellenstein et al. 2016, Selders, Fetz, Radic, et al.
2017). The neutrophils as polymorphic-nuclear cells are the hallmark of the acute
inflammation. This kind of innate immune cells got the ‘neutrophil’ name due to
both positive stainings of hematoxylin and eosin dyes. According to traditional
immunology, neutrophils are the primary responder for host defense, immune
modulation, and tissue injury (Kruger, Saffarzadeh, Weber et al. 2015, Selders,
Fetz, et al. 2017). People used to neglect the functions of neutrophils in tumor
progression due to these ideas and their short survival time (around 3 to 24 h)
(Arati Khanna-Gupta 2018).
However, the most recent results proved the phenotype heterogeneity and
functional versatility of neutrophils (Coffelt, Wellenstein, et al. 2016). Researchers
found that neutrophils play a pivotal role in chronic inflammatory diseases,
including cancer. They function in a more complicated way when compared to
traditional ideas about neutrophils (Shaul and Fridlender 2017). Specifically,
neutrophils can survive longer than researchers’ initial belief (5 or more days in
circulation), especially in the tumor microenvironment (Pillay, den Braber,
Vrisekoop, et al. 2010). Pro-inflammatory factors such as the interferon-gamma
(INFγ) in the tumor microenvironment can extend neutrophil survival time (Akgul,
Moulding and Edwards 2001), and activate tumor-associated neutrophils in
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different conditions, which results in anti-tumor and pro-tumor functions of
neutrophils (Fridlender, Sun, Kim, et al. 2009). Currently, there is increasing
evidence indicating that neutrophils are playing vital functions in the tumor
microenvironment (Coffelt, Wellenstein, et al. 2016). However, the nature of these
roles in different cancer types is still debatable (Triner, Devenport, Ramakrishnan,
et al. 2019).
Meanwhile, the population of neutrophils renders phenotypic heterogeneity
and functional versatility. However, how to clarify the polarization states of the
tumor-associated neutrophils is still under investigation. Additionally, the specific
mechanism regarding neutrophil-facilitated cancer progression remains unclear.
Neutrophil recruitment in the tumor microenvironment
The mobilization of neutrophils from bone marrow to tumor sites occurs in
three phases including expansion and maturation of pre-mature neutrophils in the
bone marrow, intravasation to circulation through attachment to endothelial cells,
and the chemotactic movement of neutrophils to tumor sites (Furze and Rankin
2008). The pre-mature neutrophils are derived from hematopoietic stem cells. The
proliferation and maturation of neutrophils require the regulation of G-CSF and
granulocyte macrophage colony-stimulating factor (GM-CSF) (Coffelt, Wellenstein,
et al. 2016). The neutrophil maturation also includes the nuclear morphology
change—the original round-shape nucleus finalizes to a segmented shaped
nucleus and surface antigen expression changes, including CD 65 and CD16
(Elghetany 2002).
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The release of neutrophils in bone marrow mainly depends on the interplay
between CXCR4 and CXCR2 and its ligands. These two receptors belong to the
CXC chemokine receptor family and are G-protein coupled receptors. CXCR4 and
CXCR2 are expressed on the surface of the neutrophil and span seven times the
neutrophil membrane (Chow and Luster 2014). The role of CXCR4 is for neutrophil
homing in the bone marrow. Higher levels of CXCR4 and its ligands (for instance,
CXCL12) will restrain the neutrophils mobility (Martin, Burdon et al. 2003, Eash,
Greenbaum, Gopalan, et al. 2010). An initial step for neutrophil movement is the
disruption of CXCR4 and its ligand expression by factors including G-CSF.
Conversely, the CXCR2 receptor is mainly responsible for the release of
neutrophils into circulation, CXCR2, CXCR2 ligands, and G-CSF co-ordinates
together to facilitate neutrophil mobilization (Furze and Rankin 2008). Antagonistic
interactions between CXCR2 and CXCR4 maintains the homeostasis of
neutrophils (Martin, Burdon, et al. 2003, Eash, Greenbaum, et al. 2010, Hong
2017). The increased expression of CXCR2 indicates the mobilization of mature
neutrophils to the circulation system. Meanwhile, the upregulation of CXCR4 on
aged neutrophils will result in them backing to the bone marrow and being digested
by macrophages (Hong 2017).
The mobilization of neutrophils to the tumor sites also requires an interplay
between CXCR2 and its ligands CXCL1-3 and CXCL5-8 (Belperio, Keane, Burdick,
et al. 2002, Sharma, Nawandar, et al. 2013). In cancer, the CXCR2 axis is the
primary player for neutrophil recruitment to the tumor sites (Fridlender and Albelda
2012). Various cell types within the tumor produce the CXCR2 chemokines,
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including tumor cells, immune cells, and cancer-associated fibroblasts (Sharma,
Nawandar, et al. 2013, Chan, Hsu, Pai, et al. 2016, Wang, Liu, Zheng, et al. 2018).
In response to tumor-derived factors, neutrophils will then move through a positive
chemotactic gradient, towards the higher concentration of the CXCR2 ligands. The
expression of CXCR2 on neutrophil cell surfaces and the production of CXCR2
ligands are both vital for this chemotactic movement(Eash, Greenbaum, et al. 2010,
Wu, Wang et al. 2012). The inhibition of CXCR2 expression in neutrophils will
result in neutrophil retention in the bone marrow and decreased mobilization (Wu,
Wang et al. 2012, Girbl, Lenn, Perez, et al. 2018).
Based on previous reports, there are several positive regulators, which lead
to an increase in neutrophil recruitment, such as G-CSF and IL17. G-CSF is a
cytokine produced by multiple cells types, including macrophage, endothelial cells
(Scapini, Lapinet-Vera, Gasperini, et al. 2000), and cancer cells (Casbon, Reynaud,
Park, et al. 2015). Apart from neutrophil mobilization, G-CSF is also known to play
a role in neutrophil proliferation, maturation, and function (Chow and Luster 2014).
G-CSF positively regulate neutrophil migration by downregulating the expression
of CXCR4 and its ligand, CXCL12 (Kim, De La Luz Sierra, Williams, et al. 2006).
Blocking the G-CSF receptor in mice ends up with impaired neutrophil mobilization.
However, experiments showed that G-CSF did not induce the chemotactic effects
on murine neutrophils, which indicates that G-CSF induced neutrophil migration
mainly depend on the indirect activity of G-CSF (Wengner, Pitchford, Furze, et al.
2008). The recruitment of neutrophils seems to be more dependent on CXCR4,
CXCR2, and their ligands (Eash, Greenbaum, et al. 2010).
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Functions of Neutrophils in the Tumor Microenvironment
The Pro-Cancer Role of Neutrophils
Tumor-associated neutrophils are generally considered a pro-tumor factor
in multiple tumor types, including breast cancer (Coffelt, Wellenstein, et al. 2016,
Shaul and Fridlender 2017). Using over 5000 cases of 25 different cancer types,
Gentles et al. indicated that higher PMN cells (including neutrophils) infiltration
would lead to the lowest overall survival for those cancer patients compared to
other leukocytes (Gentles, Newman, et al. 2015). Additionally, the higher
neutrophil to lymphocyte ratio (NLR) indicates a worse prognosis for those patients
(Coffelt, Wellenstein, et al. 2016). There are also studies regarding neutrophils
establishing a pre-metastatic niche for the malignant tumor cells (Wculek and
Malanchi 2015). These studies indicate the overall pro-tumor functions of
neutrophils in multiple cancer types.
Based on the published reports, the neutrophils play pro-tumor roles
through multiple mechanisms described below.
Neutrophil Released Reactive Oxygen Species
As mentioned before, neutrophils are the most abundant leukocytes and
are recruited to the infected site during an immune response (Kruger, Saffarzadeh,
et al. 2015). Once the pathogen invades the host tissue and starts to replicate, the
resident macrophage will respond to the pathogen with phagocytosis and secrete
factors including CXCR2 ligands, which promote mobilization of activated
neutrophils from bone marrow to the infected tissue (Zhang and An, 2007, Prame
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Kumar, Nicholls and Wong 2018). The multiple receptors on the neutrophil surface,
such as CD14, enable neutrophils to recognize and eliminate the pathogens. One
of the killing mechanisms of neutrophils to the pathogens includes phagocytosis.
Neutrophils consist of a significant part of the phagocyte system (Dale, Boxer and
Liles 2008). The phagocytes can sense and engulf the pathogens by forming
phagosome and later fusing with a lysosome(Peyron, Maridonneau-Parini and
Stegmann 2001). The enzymes in the neutrophils’ granules, for instance, NADPH
oxidase, enable the changes of pH in phagolysosome (Jankowski, Scott and
Grinstein 2002) and release the reactive oxygen species (ROS) through the
respiratory burst. The production of ROS in phagolysosome is for killing the
pathogens (Winterbourn, Kettle and Hampton 2016). However, the released ROS
by neutrophils can result in DNA base damages (Cadet and Wagner 2013), as well
as mutations (Cooke, Evans, Dizdaroglu et al. 2003), which are essential for
cancer initiation, cell proliferation, cancer-favored inflammation, immune
suppression(Uribe-Querol and Rosales 2015), and EMT in multiple cancer types,
including breast cancer (Liou and Storz 2010).
Tumor cells are usually subjected to high ROS levels in the tumor
microenvironment (Liou and Storz 2010). Moreover, ROS usually play a pro-tumor
role during progression. For instance, in breast cancer, multinucleated cells
produce ROS to stabilize HIF-1α, which promote increased production of VEGF
(Vascular endothelial growth factor) and MIF (Macrophage migration inhibition
factor), which facilitate cancer progression and chemotherapy resistance (Parekh,
Das, Parida, et al. 2018). The neutrophil released ROS can also result in epithelial
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damage and cancer favored inflammation (Coffelt, Wellenstein, et al. 2016). ROS
such as hydrogen peroxide can also function as messengers in cell signaling,
which can regulate cell signaling pathways such as the MAPK/Erk1/2pathway, the
PI 3K/Akt pathway, and the IKK/NF-κB pathway in cancer (Liou and Storz 2010).
Myeloid-derived suppressor cells (MDSCs) produced ROS results in antigenspecific tolerance of CD8+ T cells (Nagaraj, Gupta, Pisarev, et al. 2007). However,
hydrogen peroxide production by neutrophil is also considered one of the
neutrophil’s killing mechanisms to the tumor cells (Dallegri, Ottonello, Ballestrero,
et al. 1991), so the progression of cancer requires the delicate homeostasis of
ROS levels in the tumor microenvironment. The release of ROS by neutrophil can
be considered a potential therapeutic target for cancer patients.
Pro-Tumor Neutrophil-Secreted Cytokines and Chemokines
Other than ROS, neutrophils also release various cytokines and
chemokines into the tumor microenvironment (Scapini, Lapinet-Vera et al. 2000,
Singel and Segal 2016). The production of these cytokines and chemokines differ
according to different stimuli (Scapini, Lapinet-Vera, et al. 2000, Tecchio, Scapini,
Pizzolo, et al. 2013). For example, neutrophils secrete TGF-β to educate
themselves and other cell types to a pro-cancer phenotype (Fridlender, Sun, et al.
2009, Zhang, Wang, Wang, et al. 2016, Shaul and Fridlender 2017). However, in
other cases like host defense, the neutrophils may behave differently compared to
the tumor microenvironment. They react quickly in acute inflammation, and one of
their significant roles in acute inflammation is phagocytosis(Silva and CorreiaNeves 2012).
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Based on previous studies, the dominant role of neutrophil secreted factors
is pro-tumor. For example, in breast cancer, when co-cultured with human breast
cancer cell lines, the neutrophils released oncostatin M, (OSM, a member of
interleukin-6 (IL-6) superfamily) which promoted tumor progression by facilitating
angiogenesis and metastasis through the induction of VEGF expression and
increases on cancer cell invasive potential (Queen, Ryan, Holzer et al. 2005).
Additionally, researchers found that breast cancer metastasis required the
secretion of TGF-β. Tumor-associated myeloid cells expressed TGF-β, and
specific deletion of Tgfbr2 in tumor-associated myeloid cells inhibited cancer
metastasis, which indicates that the myeloid-specific TGF-β signaling is a vital part
of cancer metastasis (Pang, Gara, Achyut, et al. 2013). Tumor-associated
neutrophils can also release other pro-inflammatory cytokines into the tumor such
as IL17. As described before, IL17 can upregulate CXCR2 ligand expression to
facilitate neutrophils mobilization, which indicates a feedforward loop in this gastric
cancer model(Li, Jiang, et al. 2017). Also, IL17 itself can play a pro-tumor role
through mechanisms such as induction of the cancer stem cell feature in
pancreatic intraepithelial neoplasia cells (Zhang, Zoltan, Riquelme, et al. 2018).
Additionally, neutrophils release multiple chemokines into the tumor
microenvironment, including CXC and CC chemokines (Eash, Greenbaum et al.
2010, Dumitru, Fechner, Hoffmann et al. 2012, Tsuda, Fukui et al. 2012, Mishalian,
Bayuh, Eruslanov et al. 2014, Yan, Jiang, Pang et al. 2015, Galdiero, Varricchi,
Loffredo et al. 2018). As introduced previously, the mobility of the neutrophil to the
tumor site requires interactions between CXC chemokines in circulation and CXC
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receptors on the neutrophil membrane (Eash, Greenbaum, et al. 2010). Higher
levels of CXCR2 ligands, including CXCL8, may result in higher numbers of
recruited neutrophils on the tumor sites (de Oliveira, Reyes-Aldasoro, Candel, et
al. 2013). Therefore, the release of CXCL8 in head and neck cancer by neutrophils
may suggest a feedforward loop for neutrophil recruitment (Dumitru, Fechner, et
al. 2012). Also, in multiple cancer cases, it has been reported that neutrophils
secreted a significant amount of CC ligands (Tsuda, Fukui, et al. 2012, Mishalian,
Bayuh, et al. 2014), and the higher levels of CC ligands correlate with lower
survival rates for cancer patients (Tsuda, Fukui, et al. 2012, Yan, Jiang, et al. 2015).
The CC ligands are known chemoattractants for immune cells such as monocyte
and regulatory T cells (Sokol and Luster 2015).
Apart from neutrophils, cells such as tumor cells(Sharma, Nawandar et al.
2013), Th17 cells (Novitskiy, Pickup et al. 2011), γβ T cells (Coffelt, Kersten et al.
2015), B cells (Bodogai, Moritoh, Lee-Chang et al. 2015), lymphocytes, and
macrophages (Akgul, Moulding et al. 2001) present in the tumor microenvironment
secrete regulatory factors to facilitate cancer progression. As discussed previously,
the proliferation and maturation of neutrophils in bone marrow requires cytokines
and chemokines such as G-CSF (Bottoni and Trapasso 2009), CXCR2
chemokines, and IL17. Various cell types in the tumor microenvironment contribute
to the pool of G-CSF, CXCR2 ligands, and IL17. In the tumor microenvironment,
the primary sources of G-CSF include cancer cells (Aliper, Frieden-Korovkina,
Buzdin et al. 2014), fibroblasts (Dorsam, Bosl, Reiners et al. 2018), macrophages,
and lymphocytes (Metcalf 1989) while the major contributors of IL17 include Th17
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cells (Alves, De Medeiros Fernandes, De Araujo, et al. 2018) and γβ T cells (Patil,
Shah, Shrikhande, et al. 2016).
Factors secreted by neutrophils can educate other immune cells to a protumor type. For instance, OSM is found to regulate macrophage polarization to a
pro-tumor phenotype (M2 type) in the tumor microenvironment, and this regulation
is via mTOR signaling complex 2 (mTORC2) (Shrivastava, Asif, Singh, et al. 2018).
Neutrophils also release TGF-β into the tumor microenvironment, which promotes
the macrophages’ differentiation into M2 type macrophages (Zhang, Wang, et al.
2016). Other than interactions with macrophages, neutrophils can interact with T
cells in the tumor microenvironment (Coffelt, Kersten, et al. 2015), which can
promote cancer metastasis. For example, in a breast cancer mouse model, IL17
producing T cells upregulate the levels of G-CSF, which results in the expansion
of neutrophils and alters the neutrophil phenotype. The altered neutrophils then
produce inducible nitric oxide synthase (iNOS) to suppress the CD8 T cells’ antitumor functions in the tumor microenvironment, which results in higher metastasis
of cancer cells (Coffelt, Kersten, et al. 2015).
Neutrophil Released Enzymes
Four types of granules are present in neutrophils, the primary (azurophil),
secondary, and tertiary granules, as well as secretory vesicles. These granules
consist of various proteases. By far, the most well-studied proteases in cancer
include Cathepsin G (CG), NE, and matrix metalloprotease 9 (MMP-9). They are
all derived from neutrophil granules (Borregaard and Cowland 1997). Various
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reports indicate that they play a pro-metastasis role through mechanisms including
EMT, and extracellular matrix (ECM) remodeling (Felix and Gaida 2016). For
instance, NE and CG were found to degrade thrombospondin 1 in the premetastatic tumor microenvironment to promote cancer progression (El Rayes,
Catena, Lee, et al. 2015).
CG is a serine protease that resides in neutrophil primary granules. CG is
pre-synthesized in promyelocytes in the bone marrow and then stored in neutrophil
primary granules as active proteases. The high isoelectric points for CG (12) cause
them to be easily caught in negatively charged traps such as NETs (By Gary S.
Firestein 2017). In breast cancer, CG facilitated the E-cadherin-dependent
aggregation of mammary carcinoma cells, MCF-7 (Yui, Osawa, Ichisugi, et al.
2014), and it was through insulin-like growth factor-1 signaling (Morimoto-Kamata
and Yui 2017). Inhibition of CG resulted in less osteolysis in breast cancer, which
indicated CG as a potential therapeutic target (Wilson, Nannuru, Futakuchi, et al.
2008).
Neutrophil elastase (NE) is also known as a serine protease. Neutrophils
mostly contributed NE. Similar to CG, NE is pre-synthesized in promyelocytes and
stored in neutrophil granules in an active form. The high isoelectric points for NE
(larger than 9) also cause them to be easily trapped in negative charged NET (By
Gary S. Firestein 2017). NE is found to initiate and upregulate the cancer-related
signaling such as EGFR/MEK/ERK signaling (DiCamillo, Yang, Panchenko, et al.
2006), and PI3K signaling (Yang, Zhong, Yang, et al. 2016). Interactions between
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NE and signaling results in higher levels of pro-cancer factors such as TGF-β
(Wada, Yoshida, Hihara, et al. 2006).
NE significantly promotes cancer cell proliferation, metastasis, and therapy
resistance (Lerman, Garcia-Hernandez, Rangel-Moreno, et al. 2017, Lerman and
Hammes 2018). Cancer cells can uptake NE through neuropilin-1 if they lack
endogenous NE expression (Kerros, Tripathi, Zha, et al. 2017). Various studies
showed inhibition of NE results in the suppression of tumor progression in multiple
cancer types, including breast and prostate cancer (Caruso, Hunt and Keyomarsi
2010, Lerman, Garcia-Hernandez, et al. 2017). Breast cancer patients with higher
levels of NE correlated with lower survival rates, which indicates NE as an
independent prognostic marker (Akizuki, Fukutomi, Takasugi, et al. 2007).
Additionally, the increased expression level of NE is suggested to be a therapeutic
target for colorectal cancer (Ho, Chen, Cheng, et al. 2014).
NE and CG both promote lung metastasis by degrading anti-cancer protein
Thrombospondin 1 (Tsp1) (El Rayes, Catena, et al. 2015). Both CG and NE are
also involved in ECM remodeling in the tumor microenvironment. Moreover, ECM
remodeling is very crucial for cancer metastasis. Other than NE and CG, neutrophil
released matrix metalloproteases (MMP) such as MMP-8 and MMP-9 are also
found to be involved in ECM remodeling to facilitate cancer progression (Gregory
and Houghton 2011, Felix and Gaida 2016).
MMP is defined as a cluster of enzymes whose catalytic abilities require the
involvement of zinc (Nagase, Visse and Murphy 2006). MMP-9 is stored in
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neutrophil tertiary granules (Chakrabarti, Zee and Patel 2006). The release of
MMP-9 is delicately regulated by various cytokines and growth factors, including
the TNF, TGF-β, and the VEGF (Chakrabarti, Zee, et al. 2006, Hollborn,
Stathopoulos, Steffen, et al. 2007, Gordon, Ledee, Feuer, et al. 2009). After
release from the neutrophil granules, MMP-9 plays a pro-tumor role through
mechanisms such as remodeling of ECM by the degradation of extracellular
proteins (such as type IV collagen) (Nagase, Visse et al. 2006), membrane
cleavage (Pal-Ghosh, Blanco, Tadvalkar et al. 2011), or activating pro-tumor
factors including TGF-β (Kobayashi, Kim, Liu et al. 2014).
Compared with healthy tissues, breast cancer tissues have higher
expression levels of MMP-9, which suggests it is associated with breast cancer
development and tumor progression (Li, Qiu, Li et al. 2017). In basal-like triplenegative breast cancer, MMP-9 significantly promotes breast cancer metastasis
and angiogenesis. Silencing MMP-9 expression resulted in suppression of
malignancy (Mehner, Hockla, Miller, et al. 2014). Higher MMP-9 levels also
indicate the more aggressive phenotype and shorter survival time. Studies indicate
that higher levels of MMP-9 correlate with higher metastasis in breast cancer
patients (Yousef, Tahir, St-Pierre, et al. 2014). Positive stromal MMP-9 expression
also predicts poor survival in hormone-responsive small mammary tumors
(Pellikainen, Ropponen, Kataja, et al. 2004). All these results indicate MMP-9 as
a potential biomarker for breast cancer patients.
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NET
Historically, it was thought that neutrophil killing mechanisms included
phagocytosis and secretion of killing factors such as MMPs, CG, and NE. However,
in 2004, Brinkmann et al. discovered NET as another killing mechanism
(Brinkmann, Reichard, Goosmann, et al. 2004). This mechanism is named
NETosis. NETosis is a unique form of cell death that is characterized by the release
of de-condensed chromatin and granular contents to the extracellular space.
NETosis usually requires stimulation to neutrophils and the generation of ROS by
NADPH oxidase (Fuchs, Abed, Goosmann, et al. 2007). Initial studies report the
neutrophils after being activated by stimuli such as CXCL8 or LPS will produce the
fragile and fiber-like net by ejecting nuclear chromatin attached with proteases
(such as NE, CG, MMP-9, myeloperoxidase (MPO)) to entangle and eliminate the
pathogens. This process requires the rupture of the cytoplasmic membrane
(Erpenbeck and Schon 2017). However, there are also reports regarding
neutrophils forming NET through the release of mitochondria DNA. This process
does not require the lytic death of neutrophils (Yousefi, Mihalache, Kozlowski, et
al. 2009, Pilsczek, Salina, Poon et al. 2010, Erpenbeck and Schon 2017).
Additionally, NET plays a regulatory role in multiple diseases (including cancer) by
activating dendritic and T cells(Berger-Achituv, Brinkmann, Abed, et al. 2013).
Neutrophils are also activated and form NET in the tumor microenvironment.
Based on previous studies, NET plays a pro-tumor role during tumor progression
(Tohme, Yazdani, Al-Khafaji, et al. 2016, van der Windt, Sud, Zhang, et al. 2018).
There is evidence that indicates the NET directly functions on tumors cells, which
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enhances their proliferation through proteases such as NE on the NET, or through
activating signaling pathways such as the NF-κB (Sangaletti, Tripodo, Vitali, et al.
2014). Additionally, in a lung cancer model, NET trapped the circulating lung
carcinoma cells and promoted tumor cell metastasis (Cools-Lartigue, Spicer,
McDonald, et al. 2013). Further studies demonstrate the capture of cancer cells by
neutrophils is through β1-integrin expressions on both cancer cells and NETs
(Najmeh, Cools-Lartigue, Rayes, et al. 2017).
When compared to healthy controls, the levels of NET increased in cancer
patients’ plasma (lung cancer, pancreatic adenocarcinoma, and bladder cancer)
(Oklu, Sheth, Wong, et al. 2017). Furthermore, in Ewing sarcoma, patients with
higher levels of NET have metastasis and early relapse after intensive
chemotherapy treatment (Berger-Achituv, Brinkmann, et al. 2013). Similarly,
according to these findings, the levels of NETs in colorectal cancer patients are
also significantly higher than healthy controls. Adverse patient outcomes are
associated with increased preoperative NETs production (Richardson, Hendrickse,
Gao-Smith, et al. 2017). These results indicate that NETs could be considered a
potential prognostic marker and therapeutic target.
In breast cancer, LPS-activated neutrophils awaken the dormant breast
cancer cells by producing NET. The produced NET remodels laminin through the
MMP-9 and NE proteases on the NET. The remodeled laminin further activates
integrin α3β1 signaling to awaken the breast cancer cells. Inhibiting the formation
of NET by DNase I digestion or by inhibition of protein arginine deiminase 4
prevents the activation of dormant cancer cells (Albrengues, Shields, Ng et al.
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2018). Additionally, metastatic breast cancer cells are also able to activate
neutrophils and promote the formation of NET in the absence of infection. The
activation of neutrophils by cancer cells is through the secretion of G-CSF.
Blocking the formation of NET by DNase I, showed the prevention of lung
metastasis in mice (Park, Wysocki, Amoozgar, et al. 2016).
Neutrophil and Therapy Resistance
Chemotherapy, as the first-line defense, is most commonly used for cancer
patients. However, one of the major challenges regarding cancer treatments
includes therapeutic resistance. Currently, researchers found the tumor
microenvironment is closely linked with therapy resistance. The changes in the
tumor microenvironment include polarization of immune cells to a pro-tumor type
as well as secretion of cytokines and proteases that promotes angiogenesis and
metastasis (Son, Lee, Youn, et al. 2017).
Neutrophils are a significant component in the tumor microenvironment and
are found to play a pivotal role in chemotherapy resistance. The potential
prognostic marker NLR is a useful marker for resistance to chemotherapy. The
higher NLR indicates higher resistance when patients receive chemotherapy drugs,
which indicates the lower survival rates for patients with multiple cancer types
(Leibowitz-Amit, Templeton, Omlin, et al. 2014, Lorente, Mateo, Templeton, et al.
2015, Gonda, Shibata, Sato, et al. 2017). Targeting neutrophils in pancreatic ductal
adenocarcinoma enhances the therapeutic response to chemotherapy drugs
(Nywening, Belt, Cullinan, et al. 2018). Neutrophils can release pro-angiogenic
factors such as MMP-9, MMP-8, and CXCL8 to promote resistance to sunitinib in
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renal cell carcinoma patients (Finke, Ko, Rini, et al. 2011). Sunitinib is a common
chemotherapy drug for multiple cancer types.
Additionally, higher levels of NE in distant metastatic breast cancer patients
is associated with a poor response to tamoxifen (Foekens, Ries, Look et al. 2003).
Neutrophil released TGF-β can also be involved in the EMT process, which
promotes tumor cells, establishing resistance to gemcitabine (Elaskalani, Razak,
Falasca, et al. 2017). Other than facilitating cancer cell resistance to chemotherapy
drugs, neutrophils also facilitate tumor cell resistance to anti-angiogenesis therapy
(Schiffmann, Fritsch, Gebauer, et al. 2019). For instance, IL17 promotes
resistance to VEGF inhibition therapy by positively recruiting neutrophils into the
tumor microenvironment (Chung, Wu, Zhuang et al. 2013).
Polarization States of Neutrophils in Cancer
Neutrophils respond differently to different stimuli (Scapini, Lapinet-Vera, et
al. 2000). Various stimuli in the tumor microenvironment are resulting in the
activation of neutrophils to anti-tumor and pro-tumor phenotypes. Similarly, with
the classification of tumor-associated macrophage in the tumor microenvironment
(M1 for anti-tumor macrophage, M2 for pro-tumor macrophage), the neutrophils
are classified into two polarization states, which are N1 (anti-tumor neutrophil) and
N2 (pro-tumor neutrophil)(Coffelt, Wellenstein, et al. 2016). Fridlender Z.G. et al.
first proposed this N1 and N2 concept in 2009 (Fridlender, Sun, et al. 2009).
According to previous studies, after exposure to regulatory factors such as G-CSF
(Casbon, Reynaud, et al. 2015) or TGF-β, neutrophils transform to the N2
phenotype. N2 neutrophils are characterized as a higher expression of pro-tumor
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factors to induce the immunosuppression in the tumor microenvironment, including
CCL2, CCL5, NE and CG, and a higher expression of arginase (Fridlender, Sun et
al. 2009, Coffelt, Wellenstein et al. 2016). Blockade of TGF-β signaling or type I
IFNs treatment results in neutrophils with a hyper-segmented nucleus, and they
are more cytotoxic (N1) to the tumor cells. N1 neutrophils have elevated
expressions of immuno-activating chemokines and cytokines, including TNFα,
ICAM-1, and FAS (Fridlender, Sun et al. 2009). The functions of neutrophils in the
tumor microenvironment seem distinct. However, as of now, unlike M1 and M2,
there is no suitable marker to indicate the N1 and N2 neutrophils in the tumor.
MDSCs in the tumor microenvironment
Under cancer and severe injury conditions, neutrophils are often associated
with a granulocytic population of gMDSCs. gMDSCs share similar morphology and
expression of cell surface markers with mature neutrophils (Gr1 or CD11b), but the
difference lies in the suppression capacity of T-lymphocytes (Shaul and Fridlender
2017). However, because MDSC and neutrophils share the identical markers, so
by far there is no method to distinguish between MDSCs and tumor-associated
neutrophils, and whether it is ‘cancer-associated neutrophils’ or ‘cancer-associated
CD11b+Ly6G+’ remains to be questioned (Coffelt, Wellenstein, et al. 2016)
The Clinical Significance of Neutrophils
Based on recent findings, neutrophils in the tumor microenvironment
usually play a pro-tumor role through the formation of NET, the release of ROS,
the secretion of pro-tumor cytokines and chemokines, and the promotion of
immunosuppression. Neutrophils emerged as the least favorable cell populations
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regarding cancer patients’ survival, which indicates significance for patients’
prognosis.
Neutrophils as A Potential Biomarker for Cancer Patients
Higher infiltration of neutrophils or NLR in cancer patients correlates with
poor clinical outcomes in multiple cancers (Quigley and Deryugina 2012, Gentles,
Newman et al. 2015, Lorente, Mateo et al. 2015, Mimica, Acevedo, Oddo et al.
2016, Suzuki, Takagi, Hikichi et al. 2016, Gonda, Shibata et al. 2017, Doi,
Nakamatsu, Anami et al. 2019, Gargiulo, Dietrich, Herrmann et al. 2019, Zhao, Li,
Yang et al. 2019). All these findings indicate that neutrophils could be considered
as a potential prognostic marker for cancer patients. As a significantly high number
of infiltrated neutrophils present in tumors compared to normal tissues, neutrophils
may also serve as a diagnostic indicator (Cheng, Chang, Chen, et al. 2012, Ho,
Chen, et al. 2014). Other than the neutrophil itself, the neutrophil releasing factors,
for instance, NE and OSM could also be considered as a prognostic and diagnostic
marker for multiple cancer types, including breast cancer (Akizuki, Fukutomi et al.
2007, Gurluler, Tumay, Guner et al. 2014, Ho, Chen et al. 2014). The detection of
neutrophil frequency or NLR, or neutrophil-releasing factors in patients’ serum is
easy, inexpensive, and applicable (Gargiulo, Dietrich, et al. 2019); however, to
make the prognostic or diagnostic results more accurate, the results may still
require the optimization by a combination of other cancer-related factors.
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Targeting Neutrophils in Cancer: The Therapeutic Plan
As the most abundant leukocyte in the human circulation system, the role
of neutrophils in tumor progression is pivotal. Additionally, neutrophils mostly play
a pro-tumor role in the tumor microenvironment. Depletion of neutrophils prevented
cancer progression in various mouse models (Granot and Jablonska 2015).
Targeting neutrophils or neutrophil-releasing factors could be regarded as a
promising therapeutic plan for cancer patients.
Based on previous research, there are mainly four ways to target
neutrophils: prevention of neutrophil expansion in the bone marrow, inhibition of
neutrophil recruitment to the tumor or circulation system, education of pro-tumor
neutrophils to an anti-tumor phenotype, and targeting neutrophil-releasing protumor factors (for instance, neutrophil released cytokines and proteases).
Clinically, one of the most applicable ways of targeting neutrophils is
through the inhibition of CXCR2, which is the positive regulator of neutrophil
mobilization. For instance, a CXCR2 antagonist, AZD5069, effectively reduced
absolute neutrophil counts in bronchiectasis patients (De Soyza, Pavord, Elborn,
et al. 2015). The AZD5069 anti-cancer effect and whether it could be included as
a therapeutic plan for cancer patients is still under investigation. Additionally, there
are studies regarding targeting neutrophils-releasing NE in cancer patients. The
application of the NE inhibitor to cancer patients mostly focuses on alleviating the
side effects of the therapeutic cancer plan. For example, after receiving the NE
inhibitor, sivelestat sodium hydrate, patients with thoracic esophagus carcinoma
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showed an improved systemic inflammatory response (Suda, Kitagawa, Ozawa,
et al. 2007). Elimination of NET by DNase I digestion is also an applicable and
easy method (Park, Wysocki, et al. 2016). However, although several clinical trials
are ongoing, no result has come out regarding targeting NET in cancer patients.
Additional preclinical and clinical studies are needed to understand better the
therapeutic effects of targeting neutrophils in cancer patients.
CONCLUSION
Currently, more attention is being directed toward tumor-associated
neutrophils and their functions in the tumor microenvironment. In recent years,
researchers have generated data regarding neutrophil’s extended survival time,
NETosis, and N1 and N2 polarization states. However, more data is still needed
to delineate the neutrophil facilitated tumor progression, and it may take time to
translate these research findings to clinical use for cancer patients. Nevertheless,
studies on neutrophils shed light on understanding the tumor microenvironment,
which promotes more research to find a cure for cancer patients.
HYPOTHESIS AND SPECIFIC AIMS
The major challenges in breast cancer treatment include chemotherapy
resistance and metastasis. When the malignancies establish resistance and
migrate to distant organs, the patients’ survival rates significantly decrease.
Recent evidence suggests that the pro-inflammatory cytokines and
chemokines, for instance, IL17 and CXCR2 ligands, play pivotal roles in cancer
progression, and most of their pro-cancer roles are through positively regulating

47

neutrophil recruitments into the tumors, which results in enhanced metastasis and
chemotherapy resistance.
Based on that, our central hypothesis of this proposed study is that tumorassociated neutrophils are playing a pro-metastasis and pro-chemotherapy
resistance role in breast cancer, and the mobilization of the neutrophil to the tumor
sites is regulated by IL17- CXCR2 axis. Based on our hypothesis, two specific aims
will be pursued.
Specific Aims
Specific Aim 1: Define the role of IL17 and CXCR2 ligands in neutrophil
recruitment in therapy resistance and metastasis in the tumor.
Specific Aim 2: Investigate the mechanism(s) and putative role of
neutrophils in chemotherapy resistance and metastasis.
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CHAPTER II: MATERIALS AND METHODS
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CELL LINE CULTURES
Cell lines and culture conditions
Murine cell lines
Murine mammary adenocarcinoma cell lines CI66, doxorubicin-resistant
(Cl66-Dox) and paclitaxel-resistant (Cl66-Pac) were maintained in Dulbecco’s
Modified Eagle Media (DMEM) (Mediatech, Hendon, VA) with 5% fetal bovine
serum (FBS) (Sigma-Aldrich, St Louis, MO), 1% vitamin, 1% glutamine, and 0.08%
gentamycin (Invitrogen, Carlsbad, CA) (Sharma, Varney et al. 2016). For the
maintenance of CI66-Dox and Cl66-Pac cells, we added 500 nM doxorubicin or
400 nM of paclitaxel in the medium, respectively.
4T1 (6-thioguanine resistant) were maintained in RPMI (Roswell Park
Memorial Institute)-1640 media (Sigma-Aldrich, St Louis, MO) with 5% fetal bovine
serum (FBS), 1% glutamine, and 0.08% gentamycin.
A murine promyelocytic cell line, MPRO Clone 2.1 (ATCC CRL-11422) was
cultured in IMDM (Iscove's Modified Dulbecco's Medium) media (Sigma, St Louis,
MO) with 4 mM L-glutamine,1.5 g/L sodium bicarbonate, 10 ng/ml murine GM-CSF
(Peprotech, Rocky Hill, NJ), and 20% heat-inactivated horse serum. The
differentiation of MPRO clone 2.1 cells to neutrophils was induced by 10 µM alltrans retinoic acid (ATRA) (Sigma, St Louis, MO) (Gupta, Shah, Malu, et al. 2014).
All the cell lines were free of mycoplasma as determined by MycoAlert Plus
Mycoplasma Detection kit (Lonza) and pathogenic murine viruses. For cell line
authentication, Human DNA Identification Laboratory, University of Nebraska
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Medical Center, Omaha, NE, USA performed the short tandem repeat (STR)
tests.31 Cultures were maintained for no longer than six weeks after recovery from
frozen stocks.
Human cell lines
The human cell line MDA-MB-231 was maintained in DMEM (Mediatech,
Hendon, VA) with 5% FBS, 1% vitamins, 1% glutamine, and 0.08% gentamycin
(Invitrogen, Carlsbad, CA).
All the cell lines were free of mycoplasma as determined by MycoAlert Plus
Mycoplasma Detection kit (Lonza) and pathogenic murine viruses. For cell line
authentication, Human DNA Identification Laboratory, University of Nebraska
Medical Center, Omaha, NE, USA performed the short tandem repeat (STR)
tests.31 Cultures were maintained for no longer than six weeks after recovery from
frozen stocks.
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IN VITRO CELL-BASED ASSAYS
Cell Viability Assay
MDA-MB-231, Cl66, Cl66-Dox, and Cl66-Pac cells were plated in triplicate
at a density of 5000 cells/well in a 96-well plate and incubated in a CO2 incubator
overnight. The following day, the cells were treated with different concentrations of
IL17 for 24 hours, or IL17 together with doxorubicin or paclitaxel for 72 hours. We
added MTT [(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide], EMD
Millipore Corp, Burlington, MA) (2mg/ml) to each well followed by incubation in a
CO2 incubator for 2-4 hours. The media was aspirated, and 100µL of dimethyl
sulfoxide (DMSO) was added to each well. The plates were read using an ELx800
(Bio-Tek, Winooski, VT) plate reader.
Percent viability was calculated:100 X ([Absorbance of the treatmentAbsorbance of the control group]/ average of the control group). Percent inhibition
was calculated: 100 X ([Absorbance of the control group - Absorbance of the
treatment group]/ average of the control group).
Cell Viability Assay For ERK Inhibitors response
Cl66, Cl66-Dox, and Cl66-Pac cells were plated in triplicate at a density of
5000 cells/well in a 96-well plate and placed in a CO2 incubator overnight. Then
the cells were treated with ERK signaling inhibitor PD98059 (Calbiochem,
Gibbstown, NJ) with or without IL17 (10ng/ml) for 24 hours and then proceeded for
MTT assay and ELISA.
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The following day, we collected the serum-free supernatant, replaced them
with new fresh media, then added MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5Diphenyltetrazolium Bromide, EMD Millipore Corp, Burlington, MA) (2mg/ml) to
each well followed by incubation in a CO2 incubator for 2-4 hours. The media was
aspirated, and 100 µL of DMSO was added to each well. The plates were read
using an ELx800 (Bio-Tek) plate reader. Percent viability was calculated:
100*([Absorbance of the treatment- Absorbance of the control group]/ average of
the control group).
WST (Water Soluble Tetrazolium Salt) assay for cell proliferation
The supernatant of Cl66, Cl66-Dox, and Cl66-Pac was collected after 24
hours in cell density of 3*105 per well and treated to differentiated and
undifferentiated MPRO Clone 2.1 cells. The supernatant was diluted in 1:1, 1:5,
1:10, and 1:100 dilution. We used serum-free DMEM as a control. The results were
read under the wavelength of 450 nm using an ELx800 (Bio-Tek, Winooski, VT)
plate reader.
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Isolation of murine neutrophils
The female BALb/c mice were injected intraperitoneally (i.p.) with 1ml
thioglycollate and euthanized 24 hours later.

Peritoneal exudate cells were

isolated after injection of 5 ml Hank's Balanced Salt Solution (HBSS) into the cavity
by syringe. The harvested cells were washed and counted. More than 90% of cells
were polymorphonuclear cells as determined by cytochemistry (Pillay, Tak, Kamp,
et al. 2013).
Chemotactic assay
Corning Costar Transwell cell culture inserts (12 mm diameter, pore size 3
µm) were used to study the migration of murine neutrophils and differentiated
MPRO clone 2.1 cells. Murine neutrophils (2×107 cells/ml) and MPRO clone 2.1
cells (2×107 cells/ml) with/without treatment of 3nM CXCR2 antagonist SCH
527123 (obtained from Schering-Plough Research Institute) for four hours was
added to the top of the transwell. Treatments (Cl66 serum-free supernatant, Cl66Dox serum-free supernatant, Cl66-Pac serum-free supernatant, Cl66 serum-free
supernatant after treated with 10ng/ml IL17 for 24 hours, Cl66-Dox serum-free
supernatant after treated with 10 ng/ml IL17 for 24 hours, and 10ng/ml Cl66-Pac
serum-free supernatant after treated with IL17 for 24 hours) and controls (serumfree media as a negative control and 10% serum-containing media as a positive
control) were added to the carrier plates. After incubating for 1 to 4 hours at 37 °C,
cells on the top of the transwell were removed, fixed, and stained using Hema-3
(Thermo Fisher Scientific, Waltham, Massachusetts). The number of neutrophils
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was quantitated using a Nikon Eclipse E800 microscope equipped with a Nikon
digital sight DS-5M camera at a magnification of 200X using NIH Image J software.
Knockdown of CXCR2 in tumor cells
The CXCR2 knocking down method is as described in our previous
research (Nannuru, Sharma, Varney, et al. 2011). We silenced the CXCR2
expression by using short hairpin RNA (shRNA) technology. shRNAs targeting
CXCR2 :(2sh-CCC CAA TAC AGC AAA CTG GCG GAT) and control shRNA
targeting a sequence unrelated to known mouse genome sequences were used.
Cl66 cells were transfected with the control or CXCR2 shRNA plasmid vectors by
using Lipofectamine reagent (Invitrogen, Waltham, MA). Transfected clones of
Cl66 (Cl66-control and Cl66-shCXCR2) cells consistently expressed either
shCXCR2 or vector control were isolated and maintained in medium supplemented
with 1000 μg/ml of G418-sulfate (Invitrogen, Carlsbad, CA). To avoid clonespecific effects, pooled cultures were used for all the experiments.
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ANIMAL MODEL AND DETAILS OF IN VIVO STUDIES
Study approval
All the mice used for this study were maintained under specific pathogenfree conditions. All animal experiments were approved by the Institutional Animal
Care and Use Committee of the University of Nebraska Medical Center.
Syngeneic mouse models
We utilized syngeneic mouse models (immunocompetent mouse models)
to study the role of IL17-CXCR2 axis in tumor progression and metastasis.
Chemotherapy-resistant cell transplanted mouse model: Female BALB/c
mice (6-8 weeks old) were purchased from the National Cancer Institute (Bethesda,
MD) and maintained in specific pathogen-free conditions. Orthotropic injection of
the cells (Cl66, Cl66-Dox, and Cl66-Pac) (50,000 in 50 µl of HBSS) in the
mammary fat pad lead to the formation of tumors. We monitored tumor growth and
euthanized animals when they were moribund. Tumor volume was measured twice
a week. Tumor volume (V) was calculated by formula π/6 × (smaller diameter)2 ×
(larger diameter). Tumor tissues were harvested and processed for further analysis.
CXCR2 knockdown mouse model: Female BALB/c mice (6-8 weeks old)
were purchased from the National Cancer Institute (Bethesda, MD) and maintained
in specific pathogen-free conditions. We performed orthotropic injections of Cl66
wild type cells or Cl66sh-CXCR2 cells (1 × 106 in 0.1 ml of HBSS) into the
mammary fat pad of the BALB/c mice, which lead to the formation of tumors and
spontaneous metastasis. We monitored tumor growth twice a week. Tumor volume
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was measured twice a week. Tumor volume (V) was calculated by formula π/6 ×
(smaller diameter)2 × (larger diameter). Tumor tissues were harvested and
processed for further analysis (Nannuru, Sharma, Varney, et al. 2011).
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REAGENTS AND ANTIBODIES
The CXCR2 inhibitors SCH-527123 were obtained from Schering-Plough
Research Institute. We prepared the stock by dissolving in 20% hydroxypropyl-βcyclodextrin (HPβCD; Acros Chemical St. Louis, MO). The recombinant IL17 was
obtained from (Peprotech, Rocky Hill, NJ, U.S.A). A list of all the antibodies used
for the present study is present in Table 2.1.
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GENE EXPRESSION ANALYSIS
RNA isolation
We isolated the RNA from the cells and homogenized tissues using Trizol
reagent (Invitrogen, Carlsbad, CA). Generally, after washing cells with
PBS/grinding the tissue, we lysed the cells with Trizol (1 ml for 5 to 10 × 106 cells).
After homogenization, we added chloroform to the samples (0.2 ml according to
1ml of Trizol). After vigorously shake and centrifuge at 12,000 g for 15 minutes, we
transferred the aqueous phase and added the equal volume of isopropanol. After
centrifugation, we collected the pellet and washed the pellet with 75% ethanol. We
air-dried the sample and dissolved with DEPC-treated water. We measured the
concentration of RNA using Thermo Scientific NanoDrop 2000 Spectrophotometer
(Thermo Scientific, Carlsbad, CA).
Quantitative RT-PCR
Quantitative RT-PCR method was performed to analyze gene expression.
We detected the gene expressions in Cl66, Cl66-Dox, and Cl66-Pac cells and
tumors. In brief, 2-5 µg total RNA was reverse-transcribed using SuperScriptTM
Reverse Transcriptase (Invitrogen) and oligo (dT) primers. We detected murine
CXCR2,

CXCL1,

CXCL2,

CXCL3,

CXCL5,

CXCL7,

IL17, IL17R,

and

Hypoxanthine-guanine phosphoribosyltransferase (HPRT) (for normalizing gene
expression) expression, together with human IL23, IL6,G-CSF and β-Actin (for
normalizing gene expression); qRT-PCR reactions were prepared using cDNA,
iTaq Universal SYBR Green Master Mix (Bio-RAD, Hercules, CA), gene-specific
primers (Table 2.2), and using the BIO-RAD CFX ConnectTM Real-Time PCR
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Detection System (Bio-Rad, Hercules, CA). BIO-RAD CFX Manager 3.1 software
was used to run the analysis. Mean Ct values of the target genes were normalized
to mean Ct values of the endogenous control, HPRT (mouse) or β-Actin (human);
[-∆Ct = Ct (HPRT or β-Actin ) – Ct (target gene)]. We further normalized it with
parent Cl66 (2(-∆∆Ct)).
We also examined the gene expressions in MPRO cells. The differentiated
(cell density of 1*107 cells / well) and undifferentiated MPRO clone 2.1 cells (cell
density of 2*107 cells / well) were treated with supernatant of Cl66, Cl66-DOX, and
Cl66-PAC cells for 24 hours. 2 µg of RNA was reverse-transcribed using iScript
Reverse Transcriptase (Bio-rad) and 5X iScript Reaction Mix. We used Quant
Studio 3 (Thermo Fisher, Carlsbad, CA) for the detection of murine IL23, IL6, and
GAPDH (for normalizing gene expression). We prepared qRT-PCR reactions with
PowerUp™ SYBR™ Green Master Mix (Thermo Fisher, Carlsbad, CA), cDNA,
gene-specific primers, and nuclease-free water. The results were analyzed by
using Thermo Fisher Connect. Mean Ct values of the target genes were
normalized to mean Ct values of the endogenous control, GAPDH; [-∆Ct = Ct
(GAPDH) – Ct (target gene)]. We calculated the ratio of mRNA expression of target
genes versus GAPDH (2(-∆Ct)) and further normalized it with control (MPRO cells
in SF) (2(-∆∆Ct)). Melting curve analysis was performed to check the specificity of
the amplified product.
Melting curve analysis was performed to check the specificity of the
amplified products. The details of gene-specific primers are in Table 2.2.
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PROTEIN ANALYSIS
Protein Isolation
After washing the cells, we isolated the protein using the Membrane Lysis
Buffer, M-PER (Pierce, Rockford, IL) with protease inhibitor (Complete Mini, Roche
Diagnostics, Mannheim, Germany) added. After incubation for 30 minutes on ice,
samples were centrifugated at 10,000 rpm at 4°C. The protein concentrations were
determined by Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL).
Zymography
Cl66, Cl66-Dox, and Cl66-Pac are seeded in 6-well plate in cell density of
3x105 per well overnight. Cell-free supernatant was collected after 24 hours then
added to the undifferentiated MPRO Clone 2.1 cells (MRPO clone 2.1 in a density
of 1x107 cells per well). After 3 hours, cell-free supernatant was collected and
ready for zymography. The samples were electrophoresed on 10% sodium
dodecyl sulfate (SDS) polyacrylamide gels with 1% gelatin. After washing, we
incubated the gel with an incubation buffer overnight, then stained the gel with
staining buffer made of coomassie blue R-250 (0.1%), acetic acid (10%), methanol
(30%) and water.
Western blot
Cl66, Cl66-Dox, and Cl66-PAC cells are plated in the cell density of 3x105
per well in a 100mm dish overnight, then incubated for 24 hours in serum-free
media. We detected the protein levels of ERK1 in Cl66, Cl66-Dox, and Cl66-Pac
by using the ERK 1 Antibody (K-23): sc-94 antibody (Santa Cruz, Dallas, Texas);
the levels of phosphorylated p44/42 MAP kinase were detected by Phospho61

p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (Cell signaling technology, 9101,
Danvers, MA). We also detected the levels of p-IκB-α using anti-p-IκB-α antibodies
(Santa Cruz, Dallas, Texas). Actin and HSP70 were used as control. We detected
actin and HSP70 levels (control) by using the anti-Actin antibody (A2066, SigmaAldrich, St. Louis, MO) and HSP 70/HSC 70 Antibody (W27): sc-24 (Santa Cruz
Biotechnology, Dallas, Texas).
The denatured samples were electrophoresed on 10% SDS polyacrylamide
gels. After electrophoresis, the results were transferred to Immobilon-p Transfer
membranes (Millipore, Billerica, Massachusetts). After blocking in blocking buffer,
we incubated the membranes with primary antibodies overnight (Table 2.1). After
washing, the membrane was further incubated with secondary antibodies. We
visualized our results using a Luminata Forte Western HRP Substrate Kit (Millipore,
Billerica, MA). We obtained our results by using the LuminataTM Forte (Millipore)
on Molecular Imager® Gel Doc™ XR System (BIO-RAD) using Image Lab version
5.2.1.
Enzyme-linked immunosorbent assay (ELISA)
Cell-free supernatants were collected after treatment of cells with different
concentrations of recombinant murine IL17 (Peprotech, Rocky Hill, NJ) for 24hrs.
Cell-free supernatants were also collected after treatment of cells with ERK
signaling inhibitor PD98059 or NF-κB signaling inhibitor BMS-345541 for 24hrs.
CXCL1 (Catalog Number DY453), CXCL5 (Catalog Number DY452), IL17
(Catalog Number DY421) ELISA kits (R&D Systems, Minneapolis, MN) were used
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according to the manufacturer’s instruction. Briefly, wells were coated with primary
antibody at 4°C overnight.

The next day, after blocking and washing, samples

and standards were added in duplicate. After incubation with the secondary
antibody, the reaction was developed and read using an ELx800 (Bio-Tek,
Winooski, VT) plate reader. Concentrations were normalized using the absorbance
reading from the cell viability assay.
Immunohistochemistry (IHC)
Slides were deparaffinized and processed for antigen retrieval using a
citrate buffer (10 mM, pH=6) or Tris-EDTA buffer (pH=9) in a pressure cooker.
Endogenous peroxidase activity and non-specific binding were blocked, and slides
were incubated with primary antibodies overnight at 4°C. The next day after
washing,

the

slides

were

incubated

with

the

secondary

antibodies.

Immunoreactivity was determined using ABC reagent (Vector Laboratories,
Burlingame, CA) and DAB substrate (Vector Laboratories). Slides were
counterstained with hematoxylin. Slides without primary antibodies served as a
negative control. Images for Cl66, Cl66-Dox, and Cl66-Pac primary and metastatic
tumors were acquired with a Nikon Eclipse E800 Microscope equipped with Nikon
digital sight DS-5M Camera and NIS-Elements BR 4.13.04 software. The
representative pictures for BR8015 human breast cancer array (US Biomax,
Derwood, MD) stained with CXCL1, CXCL8, CXCR2 were acquired with a Nikon
Eclipse E800 Microscope and NIS-Elements BR 5.11.00 software. Cell number
was quantitated by counting at least five different random fields at high resolution
(200X). The composite score was calculated by multiplying the intensity score by
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the percentage of positive cells. The details of primary and secondary antibodies
are listed in Table 2.1.
Immunofluorescence (IF)
We cultured the 2.5*105 of neutrophils in conditioned serum-free media, the
supernatant of Cl66, Cl66-Dox, and Cl66-Pac in Nunc™ Lab-Tek™ Chamber Slide
(Thermo Fisher, Carlsbad, CA) for 4 hours, then fixed the cells with 10% of neutral
buffered formalin, and incubated overnight. The next day after washing, the slides
were incubated with the primary and secondary antibodies (Table 2.1) and
counterstained with the nucleic staining 4,6 diamidino-2-phenylindole (DAPI).
Immunoreactivity was determined using VectaFluor™ Duet Immunofluorescence
Double Labeling Kit (Vector Laboratories, Burlingame, CA). The representative
pictures were acquired with LSM 800 confocal microscope with ZEN blue edition
2.6.
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BIOINFORMATICS
We downloaded and analyzed the database GSE6434 (Chang, Wooten,
Tsimelzon, et al. 2005). Twenty-four females with locally advanced breast cancer
enrolled in the phase II study with the treatment of neoadjuvant docetaxel (single
agent). The patients’ biopsies (primary cancers) were collected before
chemotherapy treatment. The clinical response was assessed after the fourth cycle
at 12 weeks. After 12-weeks of treatment using docetaxel, surgical specimens
were also collected. For detection of gene expressions on the patients’ biopsies,
the Affymetrix U95Av2 GeneChip was utilized. We analyzed the CXCR1, CXCR2,
CXCL5, MPO gene expression patterns correlating with the response and de novo
resistance to docetaxel from the initial pretreatment core biopsies. The heatmap
was generated using Heatmapper (Babicki, Arndt, Marcu, et al. 2016).
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HUMAN BREAST CANCER TISSUE MICROARRAY
The tissue microarray blocks containing 50 cases of invasive ductal
carcinoma, 4 ductal-lobular mixed carcinomas, 8 invasive lobular carcinomas, 8
medullary carcinomas, 5 each of adjacent normal tissue and normal tissue were
purchased from US Biomax, Derwood, MD.
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STATISTICAL ANALYSIS
Analysis of the in vitro and in vivo data was performed using Kruskal‐Wallis
One Way Analysis of Variance on ranks with Turkey test for multiple comparisons,
and Mann-Whitney U test or two-sample t-test for comparison between two
independent groups. We analyzed the results using GraphPad Prism software
(version 6.02 & 8.1.1) (GraphPad Software, San Diego, CA) and are presented as
mean ± SEM. A p-value ≤ 0.05 was considered statistically significant.
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Table 2.1. List of antibodies

Primary

source

dilution

A kind gift from Dr.

1:1000

Strieter in UNMC

IHC

Abcam, MA, U.S.A.

1:500

antibody
Murine CXCR2

Murine CXCL1

CXCR2

Anti-GRO alpha

IHC
Murine CXCL3

CXCL3

Bioss,

1:500

Massachusetts,

IHC

U.S.A.
Murine CXCL5

CXCL5 (ENA78)

CLOUD-CLONE

1:100

CORP, Texas,

IHC

U.S.A.
Murine IL17R

Murine Th17

H168

RORγt (H190)

cells
Murine Anti-

ab5103

Histone H3

SANTA CRUZ,

1:100

Texas, U.S.A.

IHC

SANTA CRUZ,

1:200

Texas, U.S.A.

IHC

Abcam, MA, U.S.A.

1:200
IF

(citrulline R2 +
R8 + R17)
antibody
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Murine p-IκB-α

p-IκB-α Antibody

Santa Cruz, Texas,

1:500

(B-9): sc-8404

U.S.A.

Western
Blot

phosphorylated Phospho-p44/42

Cell signaling

p44/42 MAP

MAPK (Erk1/2)

technology,

kinase

(Thr202/Tyr204)

Danvers, MA, U.S.A

1:2000

Antibody
ERK

ERK 1 Antibody

Santa Cruz, Dallas,

1:1000

(K-23): sc-94

Texas, U.S.A.

Western

antibody
Actin

Blot

anti-Actin
antibody

Sigma-Aldrich, St.

1:5000

Louis, MO, U.S.A.

Western
Blot

HSP

HSP 70/HSC 70
Antibody (W27):
sc-24

Santa Cruz

1:200

Biotechnology,

Western

Dallas, Texas,

Blot

U.S.A.
Murine and

Anti-

human

Myeloperoxidase

Abcam, MA, U.S.A.

1:100
IHC

Neutrophil
Human CXCR2

IL-8RB Antibody

Santa Cruz, Texas,

1:200

(E-2): sc-7304

U.S.A.

IHC
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Human CXCL1

Anti-GRO alpha

Abcam, MA, U.S.A.

antibody

1:200
IHC

(ab86436)
Human CXCL8

anti-CXCL-8

Endogen, MA,

1:200

U.S.A

IHC

source

dilution

Biotinylated Goat

Vector Laboratories,

1:500

Anti-Rabbit IgG

CA, U.S.A.

IHC

Jackson

1:500

Secondary
antibody

Antibody
Biotinylated

Donkey Anti-goat ImmunoResearch,
IgG Antibody

PA, U.S.A.
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IHC

Table 2.2. List of primers
Gene

Primers Sequence

mCXCR2

Forward 5’-CACCGATGTCTACCTGCTGA -3’ Reverse
5’- CACAGGGTTGAGCCAAAAGT -3’

mCXCL1

Forward 5’-TCGCTTCTCTGTGCAGCGCT-3’ Reverse
5’- GTGGTTGACACTTAGTGGTCT C-3’

mCXCL2

Forward 5’-AGTGAACTGCGCTGTCAATG-3’ Reverse
5’-TTCAGGGTCAAGGCAAACTT-3’

mCXCL3

Forward 5’-GCAAGTCCAGCTGAGCCGGGA-3’
Reverse 5’-GACACCGTTGGGATGGATCGCTTT-3’

mCXCL5

Forward 5’-ATGGCGCCGCTGGCATTTCT-3’ Reverse
5’-CGCAGCTCCGTTGCGGCTAT-3’

mCXCL7

Forward 5’-TCGTCCTGCACCAGGGCCTG-3’ Reverse
5’-AAGGGGAGCCAGCGCAACAA-3’

mHPRT

Forward 5'-CCTAAGATGAGCGCAAGTTGAA-3'
Reverse 5'-CCACAGGACTAGAACACCTGCTAA-3'

mIL17

Forward 5'-TTTAACTCCCTTGGCGCAAAA-3' Reverse
5'-CTTTCCCTCCGCATTGACAC-3'

mIL17R

Forward 5'-CATCAGCGAGCTAATGTCACA-3'
Reverse 5'-AGCGTGTCTCAAACAGTCATTTA-3'

mIL23

Forward 5’-GCTGTGCCTAGGAGTAGCAG-3’ Reverse
5’- TGGCTGTTGTCCTTGAGTCC-3’
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mGAPDH Forward 5’-AGCCTCGTCCCGTAGACAAAA-3’
Reverse 5’- GATGACAAGCTTCCCATTCTCG-3’
IL1 β

Forward 5’-GCAACTGTTCCTGAACTCAACT-3’
Reverse 5’- ATCTTTTGGGGTCCGTCAACT-3’

CCL2

Forward 5’-TTAAAAACCTGGATCGGAACCAA-3’
Reverse 5’- GCATTAGCTTCAGATTTACGGGT-3’

CCL3

Forward 5’-TTCTCTGTACCATGACACTCTGC-3’
Reverse 5’- CGTGGAATCTTCCGGCTGTAG-3’

CCL4

Forward 5’-TGACCAAAAGAGGCAGACAG-3’ Reverse
5’- CTCCCCCAAAAAAACAAAAC-3’

iNOS

Forward 5’-GTTCTCAGCCCAACAATACAAGA-3’
Reverse 5’- GTGGACGGGTCGATGTCAC-3’

hIL23

Forward 5’-TGCAAAGGATCCACCAGGGTCTGA -3’
Reverse 5’- TAGGTGCCATCCTTGAGCTGCTGC -3’

hIL6

Forward 5’-CCAGCTATGAACTCCTTCTC -3’
Reverse 5’- GCTTGTTCCTCACATCTCTC -3’

hG-CSF

Forward 5’-AGACAGGGAAGAGCAGAACGG-3’
Reverse 5’- GCCAGAGTGAGGGGTGCAA

Actin

Forward 5’-TGAAGTGTGACGTGGACATC -3’
Reverse 5’- ACTCGTCATACTCCTGCTTG -3’
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CHAPTER III: THE UPREGULATION OF IL17R, CXCR2, AND CXCR2 LIGAND
EXPRESSION IN CHEMOTHERAPY RESISTANT TUMORS AND
METASTASES

This chapter in part is derived from:
Wu L, Awaji M, Saxena S, Varney ML, Sharma B, and Singh RK. IL17CXCR2 axis facilitates breast cancer progression by upregulating neutrophil
recruitment. The American Journal of Pathology, under revision. 2019

73

ABSTRACT
Breast cancer-related fatalities rank as the second leading cause of death
in the United States in 2019 (Siegel, Miller and Jemal 2019). Based on previous
studies, pro-inflammatory cytokines such as IL17, chemokines, including CXCR2
ligands, and tumor-associated neutrophils play a pivotal role in cancer progression.
Additionally, CXCR2 ligands upregulation by IL17 was reported in multiple cancers
and inflammatory cases, while CXCR2 and its ligands are the critical players for
regulating neutrophils mobility (Wu, Saxena et al. 2019). In this study, we aim to
discover the role of IL17 and CXCR2 ligands in chemotherapy resistance and
metastasis in breast cancer. We hypothesized that resistant tumor cells have
higher expressions of CXCR2 ligands; moreover, higher levels of CXCR2, CXCR2
ligands, IL17R, and IL17 present on the resistant tumors when compared to the
non-resistant tumors. The metastatic tumors have higher levels of proinflammatory factors, including CXCR2 ligands, and IL17R. We also hypothesized
that breast cancer patients with metastasis would have higher levels of CXCR2
and CXCR2 ligands expression. To demonstrate our hypothesis, we purchased
human breast cancer tissue microarray and established a syngeneic mouse model.
Mice were injected with Cl66 murine mammary tumor cells, Cl66 cells resistant to
doxorubicin (Cl66-Dox), or paclitaxel (Cl66-Pac). We observed higher levels of
IL17R, CXCR2 chemokines, and CXCR2 in tumors generated from Cl66-Dox, and
Cl66-Pac cells in comparison with tumors generated from Cl66 cells. Tumors
generated from Cl66-Dox and Cl66-Pac cells had higher infiltration of neutrophils
and T helper 17 cells. In comparison with primary tumor sites, there were increased

74

levels of CXCR2, CXCR2-ligands, and IL17R within the metastatic lesions. In
human breast cancer tissue microarray, we also observed that CXCR2 and
CXCR2 ligand levels were higher in metastatic breast cancer patients. In all, the
data obtained from this study demonstrated higher levels of CXCR2, CXCR2
ligands, and IL17 present on the resistant tumor sites, while tumors with higher
metastatic ability possessed higher levels of CXCR2 and CXCR2 ligands.
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INTRODUCTION
Breast cancer is one of the most common cancer types for women globally.
The American Cancer Society estimated 268,600 new breast cancer cases and
41,760 death from breast cancer in the United States for 2019(Siegel, Miller, et al.
2019). The existing systemic treatments for breast cancer patients include
immunotherapy and chemotherapy (Miller, Siegel, Lin, et al. 2016). Currently, the
most commonly used chemotherapy agents for breast cancer are paclitaxel and
doxorubicin (Perez 2001; Tampaki, Tampakis, Alifieris, et al. 2018). Therapyresistant cancer cells can promote tumor recurrence and reduce patients’ survival
(Ahmad, 2013). Moreover, resistant tumors tend to be highly malignant and
metastatic (Ahmad 2013, Sharma, Varney, et al. 2016, Karagiannis, Pastoriza,
Wang, et al. 2017, Yano, Takehara, Kishimoto, et al. 2017, Samanta, Park, Ni et
al. 2018). Hence, there is an urgent need to understand the biology of
chemotherapy resistance to improve survival for cancer patients.
Evidence suggests the tumor microenvironment, other than tumor cells
themselves, plays an essential role in cancer progression (Hanahan and Weinberg
2011, Wirtz, Konstantopoulos and Searson 2011). The differences between
chemotherapy-resistant

and

-nonresistant

tumor

microenvironments

may

contribute to tumor aggressiveness (Sharma, Varney, et al. 2016).
Recent studies imply the importance of IL17, CXCR2 signaling in cancer
progression, and higher levels of IL17 and CXCR2 ligands indicated lower survival
rates for cancer patients (Coffelt, Kersten et al. 2015, Sharma, Varney, et al. 2016)
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IL17 (in particular IL17A) is a pro-inflammatory cytokine, mainly produced
by T helper 17 (Th17) cells (Jin and Dong 2013) and can promote tumorigenesis,
tumor proliferation, angiogenesis, metastasis, and chemotherapy resistance (Das
Roy, Pathangey, Tinder et al. 2009, Fabre, Giustiniani, Garbar et al. 2016, Patil,
Shah, Shrikhande et al. 2016, Kersten, Coffelt, Hoogstraat et al. 2017, Hurtado,
Wan, Housseau et al. 2018). IL17 exerts its pro-tumorigenic roles through the
activation of downstream signaling pathways including ERK, and NF-κB (Cochaud,
Giustiniani, Thomas et al. 2013, Fabre, Giustiniani, Garbar, et al. 2016, Shen, Sun,
Pan, et al. 2018). IL17 is also known to induce expression of CXCR2 ligands in
multiple cancer types, including breast cancer (Numasaki, Watanabe, Suzuki et al.
2005, Fabre, Giustiniani, Garbar, et al. 2016).
CXCR2 ligands (CXCL1-3, 5-8) are found to play pro-tumor progression
roles in various cancer types, including breast cancer, by promoting angiogenesis,
tumor cell proliferation and motility (Li, King, Moro et al. 2011, Sharma, Nawandar,
et al. 2013, Sharma, Varney, et al. 2016). CXCR2 ligands also mediate cancer
metastasis by modulating the recruitment of neutrophils (Coffelt, Wellenstein, et al.
2016, Steele, Karim, Leach, et al. 2016). We have previously shown that CXCR2
and its ligands are crucial for chemotherapy resistance (Sharma, Nawandar, et al.
2013). Simultaneously, an increase in the levels of CXCR2 ligands is a
consequence of chemotherapy resistance. Knocking down CXCR2 in cancer cells
enhanced the anti-tumor and anti-metastatic therapeutic response (Sharma,
Nawandar, et al. 2013).
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In this study, we hypothesized that the resistant cells secrete higher levels
of pro-tumor factors such as CXCR2 in vitro. Meanwhile, comparing with parent
tumors, higher levels of CXCR2 ligands together with IL17R, and higher
recruitment numbers of neutrophils with Th17 cells (a major contributor of IL17)
present on the resistant tumors in vivo. We also hypothesized that we would
observe higher levels of CXCR2 and CXCR2 ligands in breast cancer patients who
have established metastasis compared to patients with regional tumors.
To demonstrate our hypothesis, we examined the protein levels of CXCR2
and CXCR2 ligands both in vitro and in vivo (mouse model and patient samples).
We also investigated the Th17 cells recruitment numbers and IL17R levels in
murine tumors.
Our results showed higher levels of CXCR2, CXCR2 ligands present on
resistant tumors, metastatic tumors, and patients who had established the
metastatic tumor sites. We also observed that higher levels of IL17R on the
resistant tumor and metastatic tumor sites when compared with parental tumors
and primary tumor sites. Additionally, compared to Cl66 tumors, higher levels of
Th17 cells were on the tumors formed by Cl66-Dox and Cl66-Pac cells.
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RESULTS
Cl66, Cl66-Dox, and Cl66-Pac cell lines expressed IL17 and IL17R
To assess the relationship

between

the

IL17/CXCR2

axis

and

chemotherapy resistance, we utilized the murine breast cancer cell line Cl66, cells
resistant to doxorubicin (Cl66-Dox), or resistant to paclitaxel (Cl66-Pac). We used
qPCR to quantify the expression of IL17 (Fig 3.1A) and IL17R (Fig 3.1B) in these
cells. Both chemotherapy-resistant cell lines and parent cells showed expression
of IL17 and IL17R at the mRNA level. To confirm our findings at the protein level,
we performed ELISA to detect IL17 secreted by Cl66, Cl66-Dox, and Cl66-Pac
cells (Fig 3.1C) and immunoblotting for IL17R levels in parent and resistant cells
by Western blot (Fig 3.1D). Cl66, Cl66-Dox, and Cl66-Pac cells showed positive
protein expression of IL17 and IL17R. These results suggest that cancer cells
express IL17R and might respond to IL17 stimulation.
Resistant cells secreted higher levels of CXCR2 ligands
We have previously established that the resistant cancer cells expressed
higher levels of CXCR2 ligands than their parent cell (Sharma, Varney, et al. 2016).
To confirm our findings at the protein level, we performed ELISA to detect CXCL1
and CXCL5 levels in vitro. We observed significantly higher levels of CXCL1 and
CXCL5 in Cl66-Dox and Cl66-Pac cells as compared to parental controls (Fig 3.2
A&B).
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Drug-resistant tumors expressed higher levels of IL17-CXCR2 axis players
To define the association between the IL17-CXCR2 axis and chemotherapy
resistance, we evaluated the mRNA levels of CXCR2, CXCR2 ligands, IL17, and
IL17R in the tumors formed by parent Cl66 and drug-resistant (Cl66-Dox or Cl66Pac) cells. Cl66-Pac tumor lysates exhibited significantly higher mRNA levels of
CXCL2 (Fig 3.3B) CXCL3 (Fig 3.3C), CXCL5 (Fig 3.3D) and CXCL7 (Fig 3.3E) in
comparison with tumors formed by the parent Cl66 cell line (Fig 3.3A-D). We also
observed insignificant higher levels of CXCL1 (Fig 3.3A) and CXCR2 (Fig 3.3F) in
Cl66-Pac tumors in comparison with the parent Cl66 cells. Also, all the tumors
(Cl66, Cl66-Dox, and Cl66-Pac) expressed the IL17 and IL17R (Fig 3.3 G&H).
Cl66-Pac tumors expressed the highest mRNA levels of IL17 and IL17R compared
to Cl66 and Cl66-Dox tumors (differences are not significant).

Together, we

observed higher expression levels of CXCR2 ligands, CXCR2, IL17, and IL17R in
tumor-bearing mice injected with Cl66-Pac cells in comparison with the parent Cl66
tumors.
IHC results showed higher levels of Th17 cells, IL17R, CXCR2 and CXCR2
ligands present in the Cl66-Dox and Cl66-Pac primary tumor sites
To further confirm our observations at the protein level, we analyzed the
levels of CXCR2 (Fig 3.4A), CXCR2 ligands (Fig 3.4B-D), IL17R (Fig 3.4E), using
IHC. We observed a significant increase in CXCR2 (Fig 3.4A) and CXCL3 (Fig
3.4C) in Cl66-Dox and Cl66-Pac primary tumor sites compared to Cl66 primary
tumor sites (Fig 3.4A&C). We also observed a slight increase for CXCL1 (Fig 3.4B)
in Cl66-Pac tumors and a slight increase in CXCL5 (Fig 3.4D) in Cl66-Dox and
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Cl66-Pac tumors.

Furthermore, we observed a significant increase in IL7R

expression in the Cl66 resistant tumors in comparison with the parent Cl66 (Fig
3.4E). There are some differences between mRNA and protein levels of CXCR2
and CXCR2 ligands. However, the overall trend is similar: the resistant cells
express higher levels of CXCR2 and CXCR2 ligands. However, similar to previous
reports, we observed differences in the levels of mRNA expression and protein
levels (Guo, Xiao, Lei, et al. 2008). A significant increase in the number of Th17
cells in the Cl66-Dox tumors was observed (Fig 3.4F). We also observed a nonsignificant increase of Th17 cells in the Cl66-Pac tumor. Our results show
increased recruitment of Th17 cells, the major contributor of IL17 (Fabre,
Giustiniani, Garbar, et al. 2016), in resistant tumors; indicating higher levels of IL17
in resistant tumors.
Higher levels of CXCR2, CXCR2 ligands, IL17R levels on metastatic tumor
sites
Both IL17 and CXCR2 ligands have been demonstrated to promote tumor
metastasis, and to play vital roles within the tumor microenvironment through
recruiting tumor-promoting neutrophils to the tumor site (Jamieson, Clarke et al.
2012, Gong, Cumpian, Caetano et al. 2013, Li, Jiang et al. 2017, Kumar,
Cherukumilli, Mahmoudpour et al. 2018). We investigated whether there is a
difference in the levels of CXCR2, CXCR2 ligands, IL17R, between metastatic
tumors and primary tumors. We observed an overall increase in CXCR2 (Fig 3.5A),
CXCR2 ligands (Fig 3.5B-D), IL17R (Fig 3.5E), levels on the metastatic sites in
comparison with the expression of CXCR2 (Fig 3.4A), CXCR2 ligands (Fig 3.4B81

D), IL17R (Fig 3.4E) in primary tumors. All the metastatic tumors expressed
extremely high levels of CXCR2, CXCR2 ligands, and IL17R in comparison with
primary tumor sites, showing a different expression pattern between metastatic
tumors and primary tumors. We also observed a significantly higher number of
Th17 cells (Fig 3.5F) in the metastatic lesions of resistant tumors in comparison
with the metastatic lesions of parent cells.
CXCR2 and CXCR2 ligand levels were higher in metastatic breast cancer
patients
To access the differences between metastatic and non-metastatic tumor
microenvironments, we performed staining of CXCR2, CXCL1, and CXCL8, on the
BR8015 human breast cancer array. According to previous studies, the CXCR2
and CXCR2 ligand expressions were mostly found in breast cancer patients’
tissues, other than healthy specimens(Miller, Kurtzman, Wang, et al. 1998). We
further compared the CXCR2 and CXCR2 ligand expressions between patients
who established locally metastasis and patients with non-metastatic tumors.
Overall, we found the patients who established the metastatic sites had higher
expression of CXCR2, CXCL1, and CXCL8 on the primary tumor sites compared
to the patients who did not establish the metastatic tumor sites, although the
differences were not significant (FIG 3.6A-C).
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DISCUSSION
Breast cancer is one of the most common cancer types that afflicts women,
and there is an urgent need to understand cancer progression further, to improve
treatments and discover biomarkers for breast cancer patients (Siegel, Miller and
Jemal 2018). In this study, we report that resistant tumor cells secrete higher levels
of CXCR2 ligands both in vitro and in vivo. Meanwhile, our results demonstrate
that IL17 increases in the tumor microenvironment, particularly in therapy-resistant
tumor microenvironments. Our findings also explain why higher levels of CXCR2
ligands and IL17 are associated with lower survival rates in cancer patients
(Werner, Gessner, et al. 2011, Yang, Luo, An et al. 2017, Liu, Wang, Wang, et al.
2018), and suggests why patients who develop resistance to chemotherapy have
lower survival rates.
Our previous studies showed that resistant tumors exhibited a more
malignant phenotype, including highly metastatic and angiogenesis (Sharma,
Varney, et al. 2016). In this study, we observed overall increased levels of protumor factors (CXCR2, CXCR2 ligands, IL17R, and Th17 cells) on Cl66-Dox and
Cl66-Pac primary tumors. However, the expression patterns of CXCR2 ligands in
Cl66-Dox and Cl66-Pac tumors still differ. It might be because the differential
regulation of CXCR2 ligands also depends on chemotherapy used (Sharma,
Varney, et al. 2016). Because Cl66-Dox and Cl66-Pac received different
chemotherapy drug treatments, the phenotype and expression patterns of Cl66Dox and Cl66-Pac become different.
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We found that the metastatic tumors expressed higher levels of CXCR2,
CXCR2 ligands, and IL17R compared to the primary tumors sites. Moreover, we
cannot tell the differences between the metastatic lesions formed by Cl66 cells and
chemotherapy-resistant cells (Cl66-Dox and Cl66-Pac). However, we still
observed the differences between Th17 cell recruitments, quite possibly because
the progression of the resistant tumor cells are more dependent on the regulation
of IL17, and the limitation of the IHC detection method.
We also observed higher levels of CXCR2, CXCL1, and CXCL8 in breast
cancer patients with established metastasis in the lymph nodes compared to
breast cancer patients who only had regional tumors. However, the differences are
not significant. A possible reason for this may be that we are using the samples of
patients who just developed metastasis in regional lymph nodes. According to
previous studies, the differences would be more significant if we compared the
highly metastatic tumors with low metastatic tumors (Sharma, Varney, et al. 2016).
The malignant tumors, in general, express higher levels of CXCR2 and CXCR2
ligands compared with non-malignant tumors or healthy tissues. (Saintigny,
Massarelli, Lin et al. 2013, Sharma, Varney, et al. 2016, Xu, Lin, Wang, et al. 2018)
The increased secretion of CXCR2 ligands in metastatic lesions highlights the
differences between metastatic and primary tumor sites.
Although we observed higher levels of CXCR2, CXCR2 ligands, IL17R, and
IL17 on the resistant tumor sites; the detailed mechanisms regarding CXCR2 and
IL17 promoted cancer progression remains unknown. We will further discuss the

84

potential mechanisms regarding IL17 and CXCR2 promoted cancer progression in
later chapters.
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Figure 3.1: Expression levels of IL17 and IL17R in the parent, Cl66-Dox and
Cl66-Pac cell lines
A) Quantitative RT-PCR for the expression of IL17. B) Quantitative RT-PCR for
the expression of IL17R. C) The level of IL17 in the supernatant of Cl66, Cl66-Dox,
and Cl66-Pac, as determined by ELISA. D) The level of IL17R in Cl66, Cl66-Dox,
and Cl66-Pac, as determined by Western blot. The values are mean fold change
± SEM; unpaired t-test, assume both populations have the same SD; **P <0.01;
*P<0.05.
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Figure 3.2: Chemotherapy resistant cells (Cl66-Dox and Cl66-Pac) secreted
higher levels of CXCL1 and CXCL5
A) Levels of CXCL1 in the supernatant of Cl66, Cl66-Dox, and Cl66-Pac, as
determined by ELISA. B) Levels of CXCL5 in the supernatant of Cl66, Cl66-Dox,
and Cl66-Pac, as determined by ELISA. The values are mean fold change ± SEM;
unpaired t-test, assume both populations have the same SD; **P <0.01; *P<0.05.
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Figure 3.3: Chemotherapy resistant tumors expressed higher mRNA levels
of CXCR2 ligands
A-H) Quantitative RT-PCR for the expression of CXCR2, CXCR2 ligands, IL17,
and IL17R in primary tumors generated from Cl66, Cl66-Dox, and Cl66-Pac. The
values are mean fold change ± SEM; unpaired t-test, assume both populations
have the same SD; **P <0.01; *P<0.05.
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Figure 3.4: Higher expression of CXCR2, CXCR2 ligands, IL17R, and Th17
numbers in the primary tumors of resistant cells

A-D) Representative images and bar graphs showing IHC score of CXCR2 (A),
CXCL1 (B), CXCL3 (C), and CXCL5 (D); representative images and bar graphs
showing IHC score of IL17R (E) and Th17 (F) in the primary tumors of Cl66, Cl66Dox, and Cl66-Pac. Scale bar represents 50 µm. The values are mean ± SEM,
Mann-Whitney test; * for P<0.05; ** for P< 0.01.
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Figure 3.5: High expression of CXCR2, CXCR2 ligands, IL17R, and Th17
numbers in the metastatic tumors of resistant cells
A-D) Representative images and bar graphs showing IHC score of CXCR2 (A),
CXCL1 (B), CXCL3 (C), and CXCL5 (D); representative images and bar graphs
showing IHC score of IL17R (E) and Th17 (F) in the metastatic tumors of Cl66,
Cl66-Dox, and Cl66-Pac. Scale bar represents 50 µm. The values are mean ±
SEM, Mann-Whitney test; * for P<0.05; ** for P< 0.01.
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Figure 3.6: Breast cancer patients with lymph node metastasis expressed
higher levels of CXCR2 ligands and CXCR2
A) A higher level of CXCL1 present in breast cancer patients with lymph node
metastasis compared to patients with regional tumors. B) A higher level of
CXCL8 present in breast cancer patients with lymph node metastasis compared
to patients with regional tumors. C) A higher level of CXCR2 present in breast
cancer patients with lymph node metastasis compared to patients with regional
tumors. The values are shown as mean ± SEM, Unpaired t-test; * for P<0.05; **
for P< 0.01.
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CHAPTER IV: IL17 PROMOTED BREAST CANCER PROGRESSION
THROUGH MODULATION OF CXCR2 LIGANDS, WHICH FACILITATED
NEUTROPHIL RECRUITMENT TO TUMOR SITES

This chapter in part is derived from:
Wu L, Awaji M, Saxena S, Varney ML, Sharma B, and Singh RK. IL17CXCR2 axis facilitates breast cancer progression by upregulating neutrophil
recruitment. The American Journal of Pathology, under revision. 2019
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ABSTRACT
Cancer chemotherapy resistance and metastasis remain the major
challenges for treatments in multiple cancers, including breast cancer. More
evidence now indicates the crosstalk between IL17, CXCR2 ligands, and
neutrophils resulting in poor survival rates for breast cancer patients, which
indicates their positive roles in promoting breast cancer therapy resistance and
metastasis (Coffelt, Kersten et al. 2015, Gentles, Newman et al. 2015, Coffelt,
Wellenstein et al. 2016). In this study, we hypothesized that IL17 enhanced tumor
cell viability; meanwhile, IL17 can upregulate CXCR2 ligands through ERK or NFκB signaling, thus positively regulate neutrophils recruitment to the tumor sites. To
test our hypothesis, mice were injected with Cl66 murine mammary tumor cells
and resistant cells (Cl66-Dox and Cl66-Pac). We observed that the resistant
tumors (Cl66-Dox and Cl66-Pac) with higher levels of CXCR2, CXCR2 ligands,
and Th17 cells numbers also had higher levels of neutrophil recruitments
compared with the non-resistant Cl66 tumors. IL17 enhanced cells’ viability and
secretion of CXCR2 ligands in multiple breast cancer cell lines; meanwhile,
inhibition of NF-κB or ERK signaling significantly inhibited the secretion of the
CXCR2 ligand by Cl66-Dox. Inhibition of ERK signaling decreased the cell viability
in Cl66, Cl66-Dox, and Cl66-Pac cells; however, it did not inhibit the IL17 induced
cell proliferation. We also observed that the supernatant of Cl66-Dox and Cl66Pac cells enhanced neutrophil chemotaxis. In addition, IL17-induced neutrophil
chemotaxis was dependent on CXCR2 signaling.

Collectively, our data

demonstrated that the IL17 could promote cancer cell proliferation, and IL17-
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CXCR2 axis facilitates the recruitment of neutrophils to the tumor sites, thus
allowing them to play a cancer-promoting role in cancer progression.
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INTRODUCTION
Cancer metastasis and therapy resistance account for the majority of
cancer-associated mortality, and also remain the major challenge for cancer
treatment (Chaffer and Weinberg 2011, Housman, Byler, Heerboth, et al. 2014).
The process of cancer metastasis starts with local invasion into the surrounding
tissue, entering the circulation system (lymph and blood systems), arrival into the
distant organs, and colonization on the secondary tumor sites (Chaffer and
Weinberg 2011). The therapy resistance of tumor cells is acquired by alternations
of drug metabolisms or drug targets (Zahreddine and Borden 2013), or
adjustments in the tumor microenvironment (Senthebane, Rowe, Thomford, et al.
2017).
Breast cancer is one of the most common cancer types which happens to
females globally. Like other common cancer types, the major challenges of breast
cancer also include therapy resistance and metastasis. Various factors and
cancer-related immune cells are involved in the tumor chemotherapy resistance
process, including pro-inflammatory cytokine IL17, CXCR2 ligands (proinflammatory chemokines), and neutrophils. They are the key players for
promoting cancer progression, and numerous reports indicated them as a potential
therapeutic target for various cancer types, including breast cancer. However, the
detailed mechanism(s) remains unclear.
IL17 plays a pivotal role in inflammation and cancer progression. IL17
expressions in mice bearing lung cancer resulted in the higher expression a level
of CXCL1, together with significantly elevated neutrophil numbers in the tumor
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sites. Additionally, targeting neutrophils using anti-Ly-6G antibody results in lower
tumor burden, other than blockage of PD-1 (Akbay, Koyama, et al. 2017). IL17 is
reported to upregulate CXCR2 ligands in other cancer cases; other than CXCL1,
IL17 can also upregulate other CXCR2 ligands including CXCL2, CXCL5, and
CXCL8 (Jin and Dong 2013).
CXCR2 ligands are also playing an essential role in cancer progression.
They are known as the positive regulator for angiogenesis in cancer cases
(Sharma, Varney, et al. 2016), and most importantly, they are the crucial regulators
for neutrophil recruitments; the upregulation of CXCR2 and CXCR2 ligands result
in positive mobilization of neutrophils in bone marrow (Eash, Greenbaum, et al.
2010). Targeting CXCR2 in tumor microenvironments sequestered neutrophils in
the blood and disrupted neutrophils accumulation on the tumor site, which led to
improved chemotherapeutic responses in pancreatic ductal adenocarcinoma
(Nywening, Belt, et al. 2018).
Tumor-associated neutrophils are facilitating cancer favored inflammation,
promoting tumor initiation, growth, metastasis, and therapy resistance (Coffelt,
Wellenstein, et al. 2016). During metastasis, neutrophils can guide cancer cells
mobilizing to the metastatic sites and establish the pre-metastatic niche; they are
secreting important pro-tumor factors including MMP9, NE, and CG to further
facilitating cancer progression (Ardi, Kupriyanova, Deryugina, et al. 2007, Gong,
Cumpian, et al. 2013, El Rayes, Catena, et al. 2015). Neutrophils also positively
promote cancer therapy resistance through mechanisms such as enhancing tumor
cells proliferation (Wu, Saxena et al. 2019). As the most abundant cell population
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in the human innate immune system, the role of neutrophils in the tumor
microenvironment is crucial; however, the detailed mechanism regarding
neutrophils facilitated cancer progression remains unclear. Additionally, although
there is a theory regarding the anti-tumor and pro-tumor types of neutrophils, the
neutrophils are mostly playing a pro-tumor role in most cancer cases (Wu, Saxena
et al. 2019).
Therefore, according to the previous studies, the candidate mechanism
regarding IL17 and CXCR2 ligands promoted cancer progression might be due to
IL17’s upregulation of CXCR2 ligands, thus results in higher levels of neutrophils
recruited to the tumor sites.
In the current study, we hypothesized that IL17 promotes breast cancer
progression through upregulation of CXCR2 ligands, which stimulate the tumorassociated neutrophils to the tumor sites. To demonstrate our hypothesis, mice
were injected with parental Cl66 cells and Cl66 cells that are resistant to
chemotherapy drugs (Cl66-Dox and Cl66-Pac). We found that higher numbers of
neutrophils on the resistant tumor sites.
We also examined the role of IL17 on tumor cells proliferation and secretion
of CXCR2 ligands. We demonstrate that IL17 increased the expression of CXCR2
ligands and cell proliferation of Cl66 cells. We observed that the supernatant of
Cl66-Dox and Cl66-Pac cells enhanced neutrophil chemotaxis. In addition, IL17induced neutrophil chemotaxis was dependent on CXCR2 signaling. However,
treatment of IL17 to the tumor cells did not enhance Cl66 cells resistance to
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chemotherapy drugs, indicating IL17 promoted chemotherapy resistance is mostly
through the upregulation of CXCR2 ligands. Collectively, our data demonstrate that
the IL17-CXCR2 axis facilitates the recruitment of neutrophils to the tumor sites,
thus allowing them to play a cancer-promoting role in cancer progression.
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RESULTS
IL17A enhanced breast cancer cells proliferation
IL17 has been reported to promote breast cancer progression (Patil, Shah
et al. 2016, Akbay, Koyama, et al. 2017). However, the detailed mechanism
remains unknown. To understand the effect of IL17 on tumor cells, we treated
parental Cl66, resistant CI66 cells, and MDA-MB-231 with recombinant IL17. We
observed that treatment with IL17 promoted the proliferation of parental Cl66 and
resistant CI66 cells, and MDA-MB-231, in a concentration-dependent manner (Fig
4.1A&B).
IL17A enhanced breast cancer cells secretion of CXCR2 ligands
We observed that IL17 treatment of Cl66 and 4T1 cells enhanced the
production of CXCR2 ligands, CXCL1 (Fig 4.2A&B), and CXCL5 (Fig 4.2C), in a
concentration-dependent manner (Fig 4.2A-C). These results suggest that IL17
promotes cancer progression by facilitating the upregulation of CXCR2 ligands,
which positively promotes the mobilization of pro-cancer neutrophils to the tumor
site.
The secretion of CXCR2 ligands by IL17 might be through NF-kb or ERK
signaling
We treated the parental cell line, Cl66 and resistant cell line, Cl66-Dox with
an inhibitor of ERK or NF-κB signaling (PD98059 and BMS-345541). Interestingly,
we found that administrating inhibitors to the Cl66-Dox resulted in a significant
decrease in CXCL1 secretion, which indicated the secretion of CXCL1 by the
resistant cells might be dependent on both ERK and NF-κB signaling. However,
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both inhibitors could not inhibit the IL17 induced upregulation of the CXCR2 ligand
(Fig 4.3A-D). Additionally, administrations of ERK inhibitors to Cl66, Cl66-Dox, and
Cl66-Pac decreased the cells’ viability (Fig 4.3E-J).
We also detected the protein levels of ERK1, phosphorylated ERK1/2, and
p-IκB-α (indicator for NF-κb signaling activation) in the parent (Cl66) and resistant
tumor cells (Cl66-Dox and Cl66-Pac) by Western blot. All the cell lines consistently
expressed phosphorylated ERK1/2 and p-IκB-α (FIG 4.3 K).
IL17 did not facilitate tumor cells resistant to chemotherapy drugs
We treated parental Cl66 cells with chemotherapy drugs, doxorubicin, or
paclitaxel; with or without IL17. Treatment of IL17 did not facilitate Cl66 resistance
to chemotherapy drugs, paclitaxel, or doxorubicin (Fig 4.4A&B). These results
suggest that IL17 promotes cancer progression by facilitating the upregulation of
CXCR2 ligands, which positively promotes the mobilization of pro-cancer
neutrophils to the tumor site.
Drug-resistant tumors showed increased infiltration of neutrophils
We examined the number of neutrophils in Cl66 parent and resistant tumors
and observed significantly increased numbers of neutrophils in Cl66-Dox tumor in
comparison with Cl66 parent tumor (Fig 4.5A). We also observed a non-significant
increase of neutrophils numbers (Fig 4.5B) in the metastatic lesions of resistant
tumors in comparison with the metastatic lesions of parent cells. Additionally, the
expression of CXCL3 significantly correlated with neutrophils numbers on the
primary tumor sites (r2=0.44, p=0.001) (Fig 4.5C).
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The supernatant of chemotherapy-resistant cells induced the higher
chemotactic activity of neutrophils compared with parental cells
Based on our previous studies, the chemotherapy-resistant cells (Cl66-Dox
and Cl66-Pac) produce higher levels of CXCR2 ligands (Sharma, Varney, et al.
2016), which are crucial for promoting neutrophil recruitment to the tumor site. We
examined whether chemotherapy-resistant cells can recruit more neutrophils. We
collected the cell-free supernatant from Cl66, Cl66-Dox, and Cl66-Pac, and
isolated murine peritoneal neutrophils and performed a chemotactic assay. We
observed that the supernatant of Cl66-Dox and Cl66-Pac cells recruited
significantly higher numbers of murine neutrophils in comparison with parent cells
(Fig 4.6A).
IL17-induced neutrophil chemotaxis was dependent on CXCR2 signaling
We further treated Cl66, Cl66-Dox, and Cl66-Pac cells with 10 ng/ml
recombinant IL17 for 24 hours, then collected the supernatant and performed
another chemotactic assay with differentiated MPRO clone 2.1 cells (neutrophils).
The MPRO clone 2.1 cells are with or without treatment of CXCR2 antagonist,
SCH 527123 for 4 hours. We observed that the resistant cells recruit higher
numbers of neutrophils in comparison with the parent cells (Fig 4.7A-C). Overall,
the IL17 treated tumor cells recruited higher numbers of neutrophils and targeting
CXCR2 in these cells significantly inhibited the chemotaxis (Fig 4.7A-C). Our
results suggest that IL17 promotes chemotaxis of neutrophils through secretion of
CXCR2 ligands and blocking of CXCR2 signaling in the neutrophils can inhibit this
IL17-dependent neutrophil recruitment.
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DISCUSSION
Breast cancer is the most common cancer type that happens to women
worldwide. Chemotherapy resistance and cancer metastasis remain the major
concerns regarding breast cancer treatment and require further investigation of the
detailed mechanism. In this study, we found out that IL17 promoted tumor cells
viability, and upregulated the expression of CXCR2 ligands, promoting the
recruitment of cancer-promoting neutrophils.
Combined with experimental results in chapter III, our data suggest that
resistant cells secrete higher levels of pro-tumor factors, including IL17 cytokine,
which led to the upregulation of CXCR2 ligands, which recruited increased
numbers of neutrophils to the tumor site and promoted cancer-associated
inflammation.
We also observed increased numbers of neutrophils on the resistant tumor
sites comparing with the Cl66 tumor sites. Additionally, the expression of CXCL3
significantly correlated with neutrophils numbers on the primary tumor sites
(r2=0.44, p=0.001), indicating the regulatory role of CXCR2 ligands on tumorassociated neutrophil mobilizations.
We have reported that CXCR2 ligands can facilitate resistance of cancer
cells to chemotherapy drugs (Sharma, Nawandar, et al. 2013); however, we did
not observe that IL17 was able to facilitate tumor cell resistance to chemotherapy.
These results indicate that IL17 promotes cancer progression mostly through
upregulation of CXCR2 ligands and promotion of neutrophil chemotaxis. This
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observation indicates the importance of the tumor microenvironment in the ability
of tumor cells to develop therapy resistance.
Cancer progression and therapy resistance are due to the interactions
between cancer cells and infiltrating immune cells, other than only cancer cells or
single pro-cancer factors (Coffelt and de Visser 2015). For example, in this study,
compared with parental cells, we found the therapy-resistant cells were capable of
recruiting higher numbers of neutrophils, which are a significant component of the
myeloid cell population (Coffelt, Wellenstein, et al. 2016). The higher numbers of
neutrophils suggest an association with the higher levels of pro-tumor factors
released by neutrophils in the therapy-resistant tumor microenvironment of breast
cancer.
As the most abundant leukocytes in the innate immune system,
neutrophils promote cancer progression through multiple mechanisms, including
facilitating cancer therapy resistance and metastasis (Wu, Saxena et al. 2019). For
instance, it has been shown that neutrophils can mobilize to pre-metastatic sites
and establish a pre-metastatic niche for the tumor cells (Wculek and Malanchi
2015). Neutrophils are also found to release proteases including neutrophil
elastase, cathepsin G, and metalloprotease 9 from their primary granules, and
those proteases also play a role in cancer progression by facilitating chemotherapy
resistance, angiogenesis, and metastasis (Coffelt, Wellenstein, et al. 2016).
Moreover, neutrophils themselves can secrete factors like TGFβ, facilitating
immune suppression in the tumor microenvironment. TGFβ recently has also been
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suggested to play a part in Th17 priming (Merav E. Shaul 2017); Together these
point to a feedforward loop of neutrophil-promoted cancer progression, and higher
levels of infiltrated neutrophils decrease the survival rates of the cancer patients
(Gentles, Newman, et al. 2015). However, the detailed mechanisms regarding
neutrophils promoted cancer progression are still in need of further investigation.
Overall, our results indicate CXCR2 ligands, together with neutrophils
should be considered as potential targets and biomarkers for breast cancer
treatment; targeting neutrophils and CXCR2 ligands may be able to reduce breast
cancer chemotherapy resistance and metastasis.
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Figure 4.1: IL17 treatment enhanced the proliferation of the tumor cells
A) Relative viability of Cl66, Cl66-Dox, and Cl66-Pac cells in response to IL17
treatment compared to serum-free media. The MTT assay determined cell
viability. B) Relative viability of MDA-MB-231 cells in response to IL17 treatment
compared to serum-free media. The MTT assay determined cell viability. The
values are mean ± SEM, unpaired t-test; * for P<0.05; ** for P< 0.01.
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Figure 4.2: IL17 treatment enhanced the secretion of CXCR2 ligands in
tumor cells
A) Levels of CXCL1 in the supernatant of Cl66 cells, as determined by ELISA, in
response to IL17 treatment compared to serum-free media. B) Levels of CXCL1
in the supernatant of 4T1 cells, as determined by ELISA, in response to IL17
treatment compared to serum-free media. C) Levels of CXCL5 in the supernatant
of Cl66 cells, as determined by ELISA, in response to IL17 treatment compared
to serum-free media. The values are mean ± SEM, unpaired t-test; * for P<0.05;
** for P< 0.01.
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Figure 4.3: ERK and NFκB inhibitors inhibited the secretion of CXCL1 by
Cl66-Dox and inhibited tumor cells’ viability
A&B) Administration of ERK and NF-κB inhibitors to Cl66 cells did not inhibit the
CXCL1 expression by Cl66. C&D) Administration of ERK and NF-κB inhibitors to
Cl66 cells significantly inhibited the secretion of CXCL1 by Cl66-Dox; however,
could not inhibit the IL17 induced CXCL1 secretion. The values are shown as
mean ± SEM, Unpaired t-test; * for P<0.05; ** for P< 0.01. E-G) Administration of
ERK inhibitor inhibited the cell viability of Cl66, Cl66-Dox, and Cl66-Pac cells. HJ) Administration of ERK inhibitor did not inhibit the IL17 enhanced cell viability.
The values are shown as mean ± SEM. K) Protein levels of p-IκB-α, ERK1, and
Phospho-p44/42 MAPK in Cl66, Cl66-Dox, and Cl66-Pac cells.
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A) Representative images and bar graphs are showing neutrophil infiltration in
the primary tumors of Cl66, Cl66-Dox, and Cl66-Pac. Scale bar represents 50
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Figure 4.7: IL17 treatment enhanced neutrophils chemotaxis dependent on
CXCR2 signaling
A) Chemotaxis of differentiated MPRO cells (treated with/ without CXCR2
antagonist) in the response of supernatant of Cl66, Cl66 treated with IL17. B)
Chemotaxis of differentiated MPRO cells (treated with/ without CXCR2
antagonist) in the response of supernatant of Cl66-DOX, Cl66-DOX-treated with
IL17. C) Chemotaxis of differentiated MPRO cells (treated with/ without CXCR2
antagonist) in the response of supernatant of Cl66-PAC, Cl66-PAC treated with
IL17. The values are mean ± SEM, unpaired t-test; * for P<0.05; ** for P< 0.01.
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CHAPTER V: TUMOR-ASSOCIATED NEUTROPHILS PLAY A PRO-TUMOR
ROLE IN THE BREAST CANCER MICROENVIRONMENT

This chapter in part is derived from:
Wu L, Saxena S, Wang C, Prajapati D, Sharma B, and Singh RK. Tumorassociated neutrophils facilitate breast cancer progression through secretion of
pro-tumor factors and formation of NETs. Cancer Research, under preparation.
2019
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ABSTRACT
Breast cancer remains one of the most common cancer types experienced
by women. The major concerns regarding breast cancer treatments are that breast
cancer tumor easily establishes resistance and metastasize to remote organs.
Recent studies demonstrated the importance of neutrophils in facilitating multiple
cancer progressions, including breast cancer. In this study, we aim to research the
role of neutrophils in breast cancer microenvironments, and the mechanisms of
neutrophil stimulated cancer progression. We also want to investigate the
differences of the chemotherapy-resistant tumor microenvironment and the nonresistant tumor microenvironment by researching the neutrophils’ pro-tumor
mechanisms. In this study, we hypothesized that neutrophils played a pro-tumor
role in cancer progression, and neutrophils promote cancer chemotherapy
resistance and metastasis through the secretion of proteases including MMPs,
cytokines or chemokines such as CCLs, and through the formation of NETs. Our
results showed significantly enhanced viability for neutrophils cultured in the
supernatant of tumor cells compared to serum-free media. Moreover, compared to
the supernatant of Cl66, the supernatant of Cl66-Dox and Cl66-Pac significantly
enhanced the viability of neutrophils. Neutrophils cultured in the supernatant of
resistant cells started to secrete MMP2 and MMP9; meanwhile, neutrophils started
the formation of NETs in the cancer cells supernatant. The neutrophils also started
to express significantly higher levels of pro-tumor factors such as IL1β, CCLs, and
iNOS. Lastly, mice received chemotherapy treatment significantly reduced the
recruitment of neutrophils, which indicated the therapeutic effects of paclitaxel.
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INTRODUCTION
Breast cancer-related fatalities rank as the second leading cause of death
in the United States in 2019 (Siegel, Miller, et al. 2019). The current therapeutic
plan for breast cancer patients includes surgery and chemotherapy drugs. The
current chemotherapy drugs for breast cancer patients include doxorubicin and
paclitaxel (Miller, Siegel, et al. 2016)). Chemotherapy drugs like doxorubicin and
paclitaxel mostly target rapidly dividing cells, which are especially sensitive to DNA
synthesis or mitotic spindle interruption(Bagnyukova, Serebriiskii, Zhou, et al.
2010). However, cancer cells can establish resistance and metastasize to remote
organs through multiple mechanisms, including upregulating inflammatory
chemokine or cytokine production in tumor cells upon chemotherapy drug
exposure (Sharma, Varney et al. 2016, Edwardson, Boudreau, Mapletoft, et al.
2017). Upregulation of chemokines and cytokines will either directly function on
tumor cells or result in the upregulation of other pro-tumor factors, which will further
contribute to cancer progression (Wu, Saxena et al. 2019). Consequently, the
patients who have established chemotherapy resistance indicate significantly
lower survival rates compared with patients who are sensitive to chemotherapy
drugs (Alfarouk, Stock, Taylor, et al. 2015). Therefore, to establish an optimized
therapeutic plan for cancer patients, there are urgent needs to delineate the
precise mechanisms regarding tumor chemotherapy resistance and cancer
progression.
According to previous studies, the CXCR2 and CXCR2 ligands (CXCL1-3,
5-8) play pro-tumor roles in multiple cancer types, including breast cancer (Sharma,
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Nawandar, et al. 2013). CXCR2 is a G protein-coupled receptor that belongs to the
CXC chemokine receptor family. The interaction between CXCR2 and its ligands
cause the mobilization of neutrophils through a chemotactic way (Furze and
Rankin 2008). CXCR2 and CXCR2 ligands are also considered as pro-tumor
factors in multiple cancer types, including breast cancer (Sharma, Nawandar, et al.
2013). Breast cancer cells upregulate CXCR2 ligands expression when they
receive chemotherapy treatments (Sharma, Nawandar, et al. 2013). The
upregulation of CXCR2 ligands results in higher recruitment of neutrophils into the
tumor sites, which further facilitate tumor chemotherapy resistance and metastasis
(Wu, Saxena et al. 2019). Targeting CXCR2 in tumor cells led to an enhanced
chemotherapeutic response, inhibition of mammary tumor growth, angiogenesis,
and lung metastasis (Sharma, Nawandar, et al. 2013).
Neutrophils—the hallmark of inflammation—are also the most abundant
white blood cells in the human immune system, constitute a significant part, and
play vital roles in the tumor microenvironment (Wu, Saxena et al. 2019). The role
of neutrophils in the tumor microenvironment was initially neglected due to their
short life span, however recent studies demonstrated the neutrophils’ prolonged
survival time in the tumor microenvironment (Akgul, Moulding, et al. 2001), which
indicated neutrophils play more vital roles than researchers initially expected.
Tumor-associated neutrophils generally play a pro-tumor role in most cases,
through secretion of pro-tumor factors such as proteases (Matrix metallopeptidase
9 (MMP9), MMP2), inflammatory factors including Interleukin (IL)-1β (Wang, Wang,
Han et al. 2014, Wu, Saxena et al. 2019), CC family ligands (Tsuda, Fukui et al.
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2012, Wu, Saxena et al. 2019), and through the formation of neutrophil
extracellular traps (NETs) (Coffelt, Wellenstein et al. 2016, Wu, Saxena et al. 2019).
The neutrophil-released proteases in the tumor microenvironment can facilitate
tumor metastasis through degradation of the extracellular matrix (El Rayes, Catena,
et al. 2015, Felix and Gaida 2016); additionally, increased levels of MMP9 are also
associated with chemotherapy resistance and lower survival rates (Al-Batran,
Wirtz, Pauligk, et al. 2008). The tumor-associated neutrophils can also release protumor cytokines and chemokines such as IL-1β or CCL families into the tumor
microenvironment; the IL1-β plays a pro-tumor role through mechanisms such as
enhancing neutrophil mobilization (Li, Cao, Liu, et al. 2018), survival (Prince, Allen,
Jones, et al. 2004), and formation of NETs (Li, Cao, et al. 2018). The CCL ligands
can further recruit other immune cells, including macrophages to the tumor
microenvironment, which further encourages cancer progression. Meanwhile,
neutrophils also aid cancer progression through the generation of NETs. Recent
results indicated that NETs assist tumor metastasis and could be considered as
potential therapeutic targets in cancer patients (Papayannopoulos 2018). Gentles
et al. indicated that compared with other immune cells, higher polymorpho-nuclear
cell (PMN, including neutrophils) infiltration would lead to the lowest overall survival
in cancer patients (Gentles, Newman, et al. 2015). This suggests neutrophils as a
prognostic and therapeutic marker for cancer patients (Wu, Saxena et al. 2019);
however, to foster an optimized therapeutic plan for cancer patients, the neutrophil
facilitated cancer progression mechanism still needs to be further understood.
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In our previous studies, we already observed upregulation of neutrophilrecruiting factors (CXCR2, CXCR2 ligands, and IL17) in the chemotherapyresistant tumor sites; in the present study, we aim to research the role of
neutrophils in breast cancer and unveil the differences between chemotherapyresistant and non-resistant tumor microenvironments. We determined that
neutrophils play pro-tumor roles through multiple mechanisms, including secretion
or formation of pro-tumor factors such as MMPs and NETs. In the chemotherapyresistant tumor microenvironment, the neutrophils may contribute to higher levels
of these pro-tumor factors.
Overall, our results indicated how neutrophils influence cancer progression
through complex mechanisms and the difference between chemotherapy-resistant
and non-resistant tumor microenvironment.
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RESULTS
The supernatant of tumor cells enhanced the viability of neutrophils
According to the recent reports, the neutrophils possessed a much longer
survival time than the initially thought (Pillay, den Braber, et al. 2010). Additionally,
neutrophils can survive longer in Lewis lung carcinoma tumors other than the
spleen (Sawanobori, Ueha, Kurachi, et al. 2008). We further investigated if
neutrophils can also have elongated survival time in the breast cancer tumor
microenvironment; at the same time, researching if chemotherapy-resistant cells
(Cl66-Dox and Cl66-Pac) can result in higher neutrophil viability compared to the
non-resistant cells (Cl66). We cultured the differentiated and undifferentiated
MPRO cells in the supernatant of Cl66, Cl66-Dox, and Cl66-Pac cells. We found
that neutrophils cultured in the supernatant of cancer cells significantly enhanced
cell viability in both differentiated MPRO cells and undifferentiated MPRO cells
(FIG 5.1A-H). Meanwhile, when compared with MPRO cells cultured in nonresistant cells (Cl66), the increase of both differentiated and undifferentiated
MPRO cells’ viabilities in Cl66-Dox and Cl66-Pac cells were also significant (FIG
5.1A-H). These results indicate that the neutrophil can survive longer in the tumor
microenvironment, and chemotherapy-resistant tumors even promote tumorassociated neutrophils’ longer survival time.
Neutrophils cultured in the supernatant of cancer cells secreted pro-tumor
factors.
We cultured differentiated MPRO cells and undifferentiated MPRO cells in
the serum-free media, together with the supernatant of Cl66, Cl66-Dox, and Cl66136

Pac cells. We observed that when cultured in the supernatant of cancer cells, the
differentiated MPRO cells expressed higher levels of IL1β, CCL2, CCL3, IL23, and
iNOS (FIG 5.2A-E). Additionally, the undifferentiated MPRO cells expressed
higher levels of IL1β, CCL2, CCL3, CCL4, and iNOS (FIG 5.2F-J).
Neutrophils formed NETs in the supernatant of cancer cells
Brinkmann et al. recognized NETosis (neutrophils formation of NETs) as
another killing mechanism for neutrophils in 2004 (Brinkmann, Reichard, et al.
2004). Recent studies report that activated neutrophils in the tumor
microenvironment are also able to form NETs. The NETs produced by neutrophils
can facilitate lung cancer metastasis through capturing the circulating cancer cells
(Cools-Lartigue, Spicer, et al. 2013), or they can assist cancer progression through
the proteases that are attached to the NETs, such as MMP9 (Wu, Saxena et al.
2019). In our studies, we found that neutrophils in the breast cancer cells
supernatant started the formation of NETs (FIG 5.3A-D), indicating the neutrophils
may also facilitate cancer metastasis through the formation of NETs.
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Neutrophils cultured in the supernatant of chemotherapy-resistant cells
secreted MMP9 and MMP2
Tumor-associated neutrophils promote cancer progression through the
secretion of MMPs (Wu, Saxena et al. 2019). Breast cancer tissues expressed
significantly higher expression of MMP2 and MMP9 compared to the healthy
tissues (Li, Qiu, et al. 2017). The expressions of MMP2 and MMP9 are correlated
with tumor metastasis, and significantly influence breast cancer prognosis (Li, Qiu,
et al. 2017). The major contributors of MMP9 in the tumor microenvironment
includes neutrophils (Bekes, Schweighofer, Kupriyanova, et al. 2011). Meanwhile,
neutrophils can also contribute to MMP2 during chronic inflammation (Medeiros,
Fares, Franco et al. 2017). After cultured differentiated MPRO cells in the Cl66,
Cl66-Dox, and Cl66-Pac supernatant, we found that the MPRO cells started to
secrete MMP9 in the chemotherapy-resistant (Cl66-Dox and Cl66-Pac) media (FIG
5.4A). Moreover, MPRO cells started to secrete MMP2 when they were cultured
in the Cl66-Dox supernatant (FIG 5.4A). All these results indicated that neutrophils
in the tumor microenvironment might contribute to higher levels of MMPs, thus
facilitating cancer progression through MMPs promoted angiogenesis and
metastasis (Mehner, Hockla et al. 2014, Deryugina and Quigley 2015).
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Breast cancer patients resistant to chemotherapy expressed higher levels
of CXCR1, CXCR2, CXCL5, and MPO
In our previous studies, we observed that the chemotherapy-resistant
(doxorubicin-resistant and paclitaxel-resistant) tumor cells had higher levels of
protumor factors, such as CXCR2 and CXCR2 ligands, which results in higher
recruitment levels of neutrophils in a syngeneic mouse model. In the current study,
we compared between the breast cancer patients who were resistant to docetaxel,
one chemotherapy drug that shares a major part of the structure and acting
mechanisms with paclitaxel (Verweij, Clavel and Chevalier 1994), and the
docetaxel sensitive breast cancer patients. We found that similar to results in
mouse models, the patients who are not responsive to docetaxel had significantly
higher levels of CXCR2, CXCR1, and CXCL5; also with a significantly higher level
of MPO expressions (FIG 5.5A&Table 5.1). Additionally, the MPO is utilized as the
marker for neutrophils in the tumor microenvironment. These results indicated
higher levels of CXCR2 and CXCR2 ligands present in chemotherapy-resistant
breast cancer patients, which lead to higher levels of tumor-associated neutrophils
on the tumor sites. We also observed higher levels of IL17, NOS2, CXCL1-3,
CXCL7-8, NE, CG in resistant patients compared to chemotherapy-sensitive
patients; however, the increases were not significant (Table 5.2).
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The number of tumor-associated neutrophils varied when mice received
different treatments
We observed a significant decrease of infiltrated neutrophils on the Cl66
tumors treated with paclitaxel compared with the Cl66 tumors treated with PBS,
which indicating the therapeutic significance of the chemotherapy drug to the
tumor-bearing mice. However, when we knockdown CXCR2 in the Cl66 cells, we
observed that there is a significant increase on neutrophil numbers in the Cl66shCXCR2 tumor-bearing mice, and there is no difference between PBS or PCL10
treatment (FIG 5.6A&B).
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DISCUSSION
Since the tumor microenvironment plays a crucial role in cancer progression,
currently, researchers are focusing on investigating immuno-therapeutic medicine
for cancer patients. However, due to the complexity and diversity of the immune
cell population in the tumor microenvironment,

the clinical results for

immunotherapies are bidirectional: some patients had a significant clinical
response; while some experienced minimal or even no clinical benefit (Binnewies,
Roberts, Kersten, et al. 2018). To improve the clinical response to the current
therapeutic drugs, and the invention of new therapeutic medicine for the cancer
patients, further understanding of the tumor microenvironment is required.
Neutrophils, which constitute the most abundant white blood cell population,
play an essential role in cancer progression. According to previous studies,
neutrophils can be considered as therapeutic targets; moreover, the neutrophil to
lymphocyte ratio may function as a prognostic and predictive biomarker clinically
(Ocana, Nieto-Jimenez, Pandiella, et al. 2017).
In the current study, we found that compared to non-metastatic patients, the
breast cancer patients who had lymph node metastasis expressed higher levels of
neutrophil recruitment regulators: CXCR2, CXCL1, and CXCL8. Meanwhile, we
found that patients were not responsive to the chemotherapy drug, docetaxel,
expressed significantly higher levels of CXCR2, CXCR1, CXCL5, and MPO
(neutrophils markers), which indicated higher neutrophils and neutrophil recruiting
factors in the chemotherapy-resistant tumors, and neutrophils played a prochemotherapy resistances role.
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Neutrophils’ role in tumor progression was firstly neglected due to their short
survival time; however, recently, it has been shown that neutrophils may survive
longer in the tumor microenvironment (Wu, Saxena et al. 2019). In our studies, we
found out that the supernatant of tumor cells significantly enhanced neutrophils
viability; additionally, comparing with the supernatant of the non-resistant Cl66,
the neutrophils’ viability in the supernatant of chemotherapy-resistant (Cl66-Dox
and Cl66-Pac) was significantly enhanced. These results indicated that neutrophils
have a prolonged survival time in the breast cancer microenvironment, and they
can survive even longer in the chemotherapy-resistant tumor microenvironment.
We also observed that the neutrophils upregulated the secretion of other
pro-inflammatory factors when they were cultured in the supernatant of cancer
cells. For instance, the neutrophils expressed higher levels of IL1β when they
were cultured in the supernatant of cancer cells. IL1β is a vital neutrophil activator
and prosurvival cytokine (Prince, Allen, et al. 2004), and the elevated expression
of IL1β might be the reason for neutrophils prolonged survival time in the cancer
supernatant.
At the same time, the differentiated neutrophils and un-differentiated
neutrophils possessed the different expression patterns compared to each other.
For instance, the differentiated neutrophils expressed IL23 when cultured in the
breast cancer supernatant; interestingly, the undifferentiated neutrophils
expressed CCL4 when they were cultured in the tumor supernatant. This led us to
consider MDSCs. The MDSCs, the heterogeneous populations of myeloid-derived
cells, are commonly identified by their expression CD11b and Gr1 markers on the
142

cell surface. Because the neutrophils and MDSCs are sharing the same marker,
by far, there is no method to distinguish MDSCs and neutrophils from each other
by surface markers (Coffelt, Wellenstein, et al. 2016). However, even for
neutrophils, undifferentiated and differentiated cells can have different expression
patterns when they are exposed in the tumor microenvironment. Those differences
could be considered as the potential markers to distinguish neutrophils from the
MDSCs.
NETosis, as a newly discovered form of death for neutrophils, also plays a
pivotal role in cancer progression. We observed that the neutrophils could form
NETs in the supernatant of cancer cells. The NETs in the tumor microenvironment
can further promote cancer progression through mechanisms, including traping the
circulating cancer cells to further facilitate cancer metastasis (Coffelt, Wellenstein,
et al. 2016). Meanwhile, the proteases such as MMPs will also be attached on the
neutrophil NETs, and further promote cancer progression. However, as NET is a
concept that has been recently discovered, the exact mechanisms regarding NET
facilitated cancer progression is still in need of investigation.
We have observed that treatment of chemotherapy decreases the numbers
of neutrophils infiltrated in the tumor sites; however, knockdown of CXCR2 in the
tumor sites did not result in the decreased neutrophil recruitment numbers. A
possible reason could be because the CXCR2 is a scavenger receptor; knockdown
CXCR2 may result in higher levels of CXCR2 ligands present in the tumor
microenvironment, which recruited higher levels of neutrophils. However, the
phenotype of neutrophils infiltrated in the CXCR2 knockdown tumors remains
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unknown. As tumor-associated neutrophils may present N1 (anti-tumor) or N2
(pro-tumor) phenotype, more experiments are needed to distinguish the function
of these neutrophils in CXCR2 knockdown tumor sites.
In all, we reported that the neutrophils play a pro-tumor role through multiple
mechanisms, including secretion of MMPs, upregulation of pro-tumor factors, and
the formation of NETs. Our findings also revealed the differences between
chemotherapy resistance and non-resistance tumor microenvironments. Our
results indicated neutrophils as potential therapeutic targets, which will assist in
the development of an advanced therapeutic strategy for breast cancer patients.
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Figure 5.1: The supernatant of Cl66, Cl66-Dox, and Cl66-Pac enhanced the
viability of differentiated and undifferentiated MPRO cells
A) The supernatant of Cl66 cells significantly enhanced the survival of
differentiated MPRO cells. B) The supernatant of Cl66-Dox cells significantly
enhanced the survival of differentiated MPRO cells. C) The supernatant of Cl66Pac cells significantly enhanced the survival of differentiated MPRO cells. D)
The supernatant of Chemotherapy resistant tumor cells significantly enhanced
differentiated MPRO cells survival compared to the supernatant of non-resistant
tumor cells. E) The supernatant of Cl66 cells significantly enhanced the survival
of undifferentiated MPRO cells. F) The supernatant of Cl66-Dox cells significantly
enhanced the survival of undifferentiated MPRO cells. G) Supernatant of Cl66Pac cells significantly enhanced the survival of undifferentiated MPRO cells. H)
Supernatant of Chemotherapy resistant tumor cells significantly enhanced
undifferentiated MPRO cells survival compared to the supernatant of nonresistant tumor cells. The values are shown as mean ± SEM, Unpaired t-test; *
for P<0.05; ** for P< 0.01; *** for P ≤ 0.001; **** for P ≤ 0.0001.
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Figure 5.2: MPRO cells cultured in tumor cell supernatant upregulated protumor factors
A) Quantitative RT-PCR for the expression of IL1β, in differentiated MPRO cells
cultured in the supernatant of serum-free media, Cl66, Cl66-Dox, and Cl66-Pac
cells. B) Quantitative RT-PCR for the expression of CCL2, in differentiated
MPRO cells cultured in the supernatant of serum-free media, Cl66, Cl66-Dox,
and Cl66-Pac cells. C) Quantitative RT-PCR for the expression of CCL3, in
differentiated MPRO cells cultured in the supernatant of serum-free media, Cl66,
Cl66-Dox, and Cl66-Pac cells. D) Quantitative RT-PCR for the expression of
IL23, in differentiated MPRO cells cultured in the supernatant of serum-free
media, Cl66, Cl66-Dox, and Cl66-Pac cells. E) Quantitative RT-PCR for the
expression of iNOS, in differentiated MPRO cells cultured in the supernatant of
serum-free media, Cl66, Cl66-Dox, and Cl66-Pac cells. F) Quantitative RT-PCR
for the expression of IL1β, in undifferentiated MPRO cells cultured in the
supernatant of serum-free media, Cl66, Cl66-Dox, and Cl66-Pac cells. G)
Quantitative RT-PCR for the expression of CCL2, in undifferentiated MPRO cells
cultured in the supernatant of serum-free media, Cl66, Cl66-Dox, and Cl66-Pac
cells. H) Quantitative RT-PCR for the expression of CCL3, in undifferentiated
MPRO cells cultured in the supernatant of serum-free media, Cl66, Cl66-Dox,
and Cl66-Pac cells. I) Quantitative RT-PCR for the expression of CCL4, in
undifferentiated MPRO cells cultured in the supernatant of serum-free media,
Cl66, Cl66-Dox, and Cl66-Pac cells. J) Quantitative RT-PCR for the expression

150

of iNOS, in undifferentiated MPRO cells cultured in the supernatant of serum-free
media, Cl66, Cl66-Dox, and Cl66-Pac cells.
The values are mean fold change ± SEM; unpaired t-test, assume both populations
have the same SD; *P<0.05; **P <0.01; *** for P ≤ 0.001; **** for P ≤ 0.0001.
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Figure 5.3: Formation of NETs by MPRO cells in the supernatant of cancer
cells
A) MPRO cells are cultured in serum-free media B) Formation of NETs by MPRO
cells in the supernatant of Cl66 cells. C) Formation of NETs by MPRO cells in the
supernatant of Cl66-Dox cells. D) Formation of NETs by MPRO cells in the
supernatant of Cl66-Pac cells. The pictures were acquired under magnification of
630X. The scale bars are shown as 20 µm.
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Figure 5.4: Neutrophils cultured in the supernatant of resistant tumor cells
secreted MMP9 and MMP2
A) MPRO cells secreted MMP9 and MMP2 when cultured in the supernatant of
Cl66-Dox and Cl66-Pac. B&C) The quantification results of MMP2 and MMP9 in
representative pictures.
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Figure 5.5: Breast cancer patients resistant to docetaxel expressed higher
levels of CXCR1, CXCR2, CXCL5, and MPO
A) Patients resistant to docetaxel expressed significantly higher levels of CXCR1,
CXCR2, CXCL5, and MPO. The values are shown as mean, T-test, * for P<0.05;
** for P< 0.01.
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Table 5.1. Expression of CXCR2, CXCR1, MPO, and CXCL5 in breast cancer
patients

Resistant
(mean)
Sensitive
(mean)
t test

CXCR2

CXCR1

MPO

CXCL5

208.0888

197.2437

16.21532

19.35735

136.4454

115.5113

8.73933

13.41665

0.006245

0.024771

0.01692

0.034365

Table 5.2. Gene expressions in breast cancer patients
IL17A NOS2 CXCL3 CXCL8 CXCL6
Resistant
(mean)
Sensitive
(mean)
t test

NE

CTSG CXCL2 CXCL7 CXCL1

87.47

98.79

50.57

54.50

7.57

38.06 136.77

85.83

81.51

36.60

39.91

9.19

30.07 146.35

0.89

0.52

0.15

0.49

0.18
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Figure 5.6: Chemotherapy treatment reduced neutrophil recruitment
numbers, and targeting CXCR2 in tumor cells resulted in higher levels of
neutrophils
A) The recruitment numbers of neutrophils significantly decreased after mice
received treatment of paclitaxel; CXCR2 knockdown in tumor cells resulted in
higher levels of neutrophils in the tumor sites. B) Representative pictures of the
quantification results. The values are shown as mean ± SEM, Unpaired t-test; *
for P<0.05; ** for P< 0.01.
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CHAPTER VI: MAJOR CONCLUSIONS AND FUTURE DIRECTIONS
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INTRODUCTION
Increasing evidence has revealed the essential role of the tumor
microenvironment in cancer progression (Coffelt, Wellenstein, et al. 2016). The
immune cells in the tumor microenvironment are able to guide the tumor initiation,
therapy resistance, and metastasis. Meanwhile, the immune cells in the tumor may
also be activated or re-educated to inhibit cancer progression directly. Currently,
research has indicated targeting the tumor microenvironment as a promising
therapeutic plan for cancer patients. According to this theory, immunotherapies
such as targeting PD1 or CAR-T cell therapy were invented and being put into
clinical use. However, the clinical outcome for the cancer patients who received
the immuno-therapies are diverse: some patients received great clinical benefits
while others did not. The reason for this is due to the heterogeneity of the tumor
microenvironment. Thus, more studies are in urgent need to delineate the
mechanisms of tumor microenvironment promoted cancer progression.
Our current study focused on the neutrophils in the immune system. As
the most abundant cell population, the functions of neutrophils in cancer remains
unclear. Studies demonstrated that the neutrophils mostly facilitated cancer
progression; highly infiltrated neutrophils indicated the lower survival rates of
patients in multiple cancer types (Gentles, Newman, et al. 2015), which indicated
the clinical significance of neutrophils in cancer treatment.
This dissertation summarizes that the IL17-CXCR2 axis functions as the
positive regulator of neutrophil recruitments into the tumor sites, and the
neutrophils recruited to the tumor sites played a pro-tumor role through multiple
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mechanisms, including secretion of MMPs, other pro-inflammatory factors such as
IL1β, and also through formation of NETs. Our studies revealed the differences
between the chemotherapy resistance tumor microenvironment and the nonresistant tumor microenvironment. Moreover, our experimental results also
showed tumor cells, although derived from the same parental cells (Cl66), after
establishing a resistance to chemotherapy drugs, they may behave differently, and
progress in distinct mechanisms. (Gentles, Newman, et al. 2015)
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MAJOR CONCLUSIONS
The role of IL17 in breast cancer progression
I.

The cancer cells expressed IL17R both in vivo and in vitro, indicating it
is responsive to IL17.

II.

Increased numbers of Th17 cells were recruited to the resistant tumor
sites, indicating the higher levels of IL17 in the chemotherapy-resistant
tumor sites.

III.

The resistant tumors formed by Cl66-Dox and Cl66-Pac cells expressed
higher levels of IL17R.

IV.

The metastatic tumors expressed higher levels of IL17R compared with
primary tumors.

V.

IL17 enhanced tumor cell viability in multiple cell lines.

VI.

IL17 upregulated CXCR2 ligands in breast cancer cells lines. The
CXCL1 secretion by Cl66-Dox was much dependent on ERK and NFκB signaling.

VII.

However, IL17 did not facilitate cancer cells resistance to chemotherapy
drugs in the absence of neutrophils.

VIII.

IL17 treated Cl66, Cl66-Dox, and Cl66-Pac cells supernatant enhanced
neutrophils chemotaxis

The role of CXCR2 ligands in breast cancer progression
I.

The chemotherapy-resistant cells (Cl66-Dox and Cl66-Pac) secreted
higher levels of CXCR2 ligands in vitro.
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II.

The tumors formed by chemotherapy-resistant cells (Cl66-Dox and
Cl66-Pac) expressed higher levels of CXCR2 and CXCR2 ligands.

III.

The resistant tumors formed by Cl66-Dox and Cl66-Pac secreted higher
levels of CXCR2 and CXCR2 ligands.

IV.

The metastatic tumors expressed higher levels of CXCR2 and CXCR2
ligands.

V.

The supernatant of Cl66-Dox and Cl66-Pac, with higher levels of CXCR2
ligands, induced higher neutrophil chemotaxis activity compared to the
Cl66 cells with lower secretion levels of CXCR2 ligands.

VI.

The IL17 induced neutrophil chemotaxis was CXCR2 dependent.

VII.

The breast cancer patients who were resistant to docetaxel expressed
higher levels of CXCR2 and CXCR2 ligands.

VIII.

The breast cancer patients with established metastasis expressed
higher levels of CXCR2 and CXCR2 ligands.

The role of neutrophils in breast cancer chemotherapy resistance and
metastasis
I.

Higher numbers of neutrophils were present on the chemotherapyresistant tumors.

II.

The neutrophils expressed higher levels of pro-tumor cytokines and
chemokines such as IL1β, CCLs, when they are cultured in the
supernatant of cancer cells.

III.

The viability of neutrophils was enhanced when the neutrophils were
cultured in the supernatant of cancer cells.
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IV.

The supernatant of chemotherapy-resistant cells (Cl66, Cl66-Dox, and
Cl66-Pac) significantly enhanced neutrophil viability compared to the
supernatant of non-resistant cells (Cl66).

V.

The patients who established chemotherapy resistance had higher
neutrophils infiltrated into the tumor, compared with patients who were
responsive to chemotherapy drugs.

VI.

The neutrophils secreted MMP2 and MMP9 when they were cultured in
the supernatant of Cl66-Dox and Cl66-Pac cells.

VII.

The numbers of neutrophils decreased significantly when the tumorbearing mice received the paclitaxel treatment.

VIII.

Neutrophils started the formation of NETs when they were cultured in
the supernatant of cancer cells.

The big picture
I.

The malignant (resistant/metastasis) tumors expressed higher levels of
pro-tumor factors compared to relatively less malignant (nonresistant/primary) tumors.

II.

Our experimental results indicated the path of cancer progression, which
includes the upregulated CXCR2, CXCR2 ligands, higher recruitment of
Th17 cells, and neutrophils.

III.

The neutrophils may play an essential pro-tumor role in breast cancer
progression and chemotherapy resistance.

IV.

This study also revealed the role of neutrophils in breast cancer
progression.
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V.

IL17-CXCR2 axis, together with neutrophils, and neutrophil secreted
factors, are the potential therapeutic targets for breast cancer patients.
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FUTURE DIRECTIONS
Our studies revealed part of the cancer progression mechanism. We have
observed that increased levels of IL17 and CXCR2 ligands resulted in higher levels
of neutrophils, which resulted in cancer progression. However, there are still
question unanswered and remains to be the future direction of this study.
The potential outcome if we target neutrophils in tumor-bearing mice
We have observed that higher levels of neutrophils in the chemotherapyresistant tumor sites and neutrophils expressed factors such as MMPs to promote
cancer progression. Because of that, targeting neutrophils in cancer might be a
promising method to facilitate curing breast cancer. In future studies, we might
consider targeting neutrophils by using the GR1 neutralizing antibody in tumorbearing mice and investigate the outcome for tumor-bearing mice, especially in the
mice who are bearing chemotherapy-resistant tumor cells. To see if they can result
in better outcomes.
The potential outcome if we target IL17 in tumor-bearing mice
Our studies revealed that IL17 stimulated cancer progression; it promoted
cancer cell proliferation and secretion of CXCR2 ligands, which led to the higher
infiltration of neutrophils into the tumor sites. This led us to think about the outcome
for tumor-bearing mice if we targeted IL17 in the tumor microenvironment. We
would like to see if targeting IL17 would result in a better outcome for the mice
bearing Cl66, Cl66-Dox, and Cl66-Pac tumors.
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The potential signalings/regulators for IL17 induced CXCR2 ligands
secretion
We have observed that inhibition of ERK and NF-κB signalings resulted
in a significant decrease of CXCL1 secretion; however, we did not observe
significant inhibition on other cell lines (Cl66 and Cl66-Pac). In future studies,
experiments could be designed to research the potential signalings/regulators
involved in upregulation of CXCR2 ligands.
N1 and N2 type for tumor-associated neutrophils.
There are some studies that indicate that after modification, neutrophils
may play an antitumor role in tumor progression (Wu, Saxena et al. 2019). We
have observed that neutrophils play a pro-tumor role in our studies. As the most
abundant leukocyte, re-education of neutrophils to an anti-tumor type is a
promising method for curing cancer patients. However, by far there is no specific
marker to distinguish neutrophils from N1 or N2 type. We have to define the
neutrophils’ anti/protumor role according to patient outcomes.
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